Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
38.9 /100
Rank 52 out of 131 Industries -
Advance/Decline
205/139
-
No. of Companies344
-
Avg. Market Cap13,576
-
Price to Earning Ratio10.03
-
Price to Earning Growth Ratio1.25
-
Price to Book Ratio31.66
-
Return on Equity4.73
-
Return on Capital Employed-
-
Return on Assets2.69
-
Dividend yield 1 year %0.71 %
-
Net Profit Growth Annual YoY %5.00 %
-
Net Profit Growth Qtr YoY %93.18 %
-
Net Profit Growth Qtr QoQ %180.57 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
369,388.3
|
208.8
|
L
 -2.9%
H
207.7
214.6
|
L
 -0.3%
H
207.7
220.5
|
L
 -11.6%
H
201.8
234.8
|
L
 -8.9%
H
201.8
237.1
|
L
 11.7%
H
164.4
244.8
|
L
 30.7%
H
131.0
244.8
|
L
 92.4%
H
104.2
244.8
|
L
 252.7%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
480.2
|
3.8
|
L
 -0.5%
H
3.6
4.0
|
L
 2.2%
H
3.6
4.0
|
L
 -10.9%
H
3.6
5.0
|
L
 7.4%
H
3.3
5.0
|
L
 220.3%
H
1.1
5.0
|
L
 83.5%
H
0.4
6.0
|
L
 -85.2%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
3,981.1
|
12.5
|
L
 -1.8%
H
12.3
12.7
|
L
 5.3%
H
11.8
12.7
|
L
 -6.2%
H
11.7
13.6
|
L
 -1.4%
H
11.7
15.4
|
L
 69.1%
H
6.7
15.4
|
L
 817.6%
H
1.3
15.4
|
L
 89.1%
H
1.2
15.4
|
L
 -61.6%
H
1.2
37.2
|
| Annovis Bio Inc |
|
64.6
|
2.3
|
L
 7.6%
H
2.0
2.3
|
L
 12.3%
H
2.0
2.3
|
L
 -15.6%
H
2.0
3.0
|
L
 -37.5%
H
2.0
4.1
|
L
 74.1%
H
1.1
5.5
|
L
 -80.9%
H
1.1
22.5
|
L
 -91.9%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,982.5
|
5.4
|
L
 -4.1%
H
5.4
5.6
|
L
 6.6%
H
5
5.6
|
L
 -5.0%
H
4.9
5.8
|
L
 -25.8%
H
4.9
8
|
L
 0.4%
H
4.3
8.7
|
L
 -29.1%
H
4.0
11.5
|
L
 -83.1%
H
4.0
34.5
|
L
 -79.5%
H
4.0
38.5
|
| Bristol-Myers Squibb |
|
121,687.4
|
59.6
|
L
 -2.5%
H
59.1
60.6
|
L
 1.8%
H
59.1
62.2
|
L
 -4.4%
H
56.5
62.2
|
L
 11.5%
H
52.1
62.9
|
L
 7.8%
H
42.5
62.9
|
L
 -13.5%
H
39.4
71.1
|
L
 -5.3%
H
39.4
81.4
|
L
 -9.7%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
425.0
|
8.2
|
L
 -1.8%
H
8.1
8.4
|
L
 3.8%
H
7.9
8.5
|
L
 -6.2%
H
7.9
8.8
|
L
 -34.2%
H
7.8
14.1
|
L
 82.1%
H
4.0
14.1
|
L
 -16.7%
H
1.4
15.1
|
L
 -89.8%
H
1.4
82.3
|
L
 -76.6%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
113,290.6
|
56.7
|
L
 1.3%
H
55.9
57.2
|
L
 5.3%
H
54.1
57.2
|
L
 -0.3%
H
51.5
57.2
|
L
 14.2%
H
47.6
61.7
|
L
 55.2%
H
32.4
61.7
|
L
 55.1%
H
31.7
61.7
|
L
 55.5%
H
28.5
61.7
|
L
 35.9%
H
28.5
61.7
|
| Johnson & Johnson |
|
585,389.4
|
243.0
|
L
 -0.4%
H
241.9
247.2
|
L
 1.1%
H
240.5
247.2
|
L
 -0.9%
H
232.2
247.2
|
L
 17.2%
H
200.9
251.7
|
L
 58.6%
H
141.5
251.7
|
L
 53.3%
H
140.7
251.7
|
L
 49.3%
H
140.7
251.7
|
L
 123.8%
H
107.9
251.7
|
| Eli Lilly |
|
835,807.3
|
935.6
|
L
 -2.0%
H
930.0
957.7
|
L
 6.5%
H
883.1
976.7
|
L
 -6.8%
H
877.1
1012
|
L
 -13.4%
H
877.1
1134.0
|
L
 26.7%
H
623.8
1134.0
|
L
 163.8%
H
357.9
1134.0
|
L
 405.1%
H
178.6
1134.0
|
L
 1178.5%
H
64.2
1134.0
|
| Merck & Company |
|
298,838.0
|
120.9
|
L
 0.0%
H
119.2
121.7
|
L
 1.0%
H
117.2
122.2
|
L
 0.5%
H
112.7
122.2
|
L
 13.6%
H
105.8
125.1
|
L
 48.4%
H
73.3
125.1
|
L
 11.1%
H
73.3
134.6
|
L
 64.3%
H
69.5
134.6
|
L
 132.8%
H
50.4
134.6
|
| Novo Nordisk (ADR) |
|
164,133.8
|
37.0
|
L
 1.4%
H
35.6
37.0
|
L
 6.4%
H
35.1
37.1
|
L
 -4.0%
H
35.1
39.9
|
L
 -29.4%
H
35.1
64.2
|
L
 -40.9%
H
35.1
81.4
|
L
 -53.4%
H
35.1
148.2
|
L
 9.3%
H
33.8
148.2
|
L
 32.6%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
293,912.6
|
154.0
|
L
 -0.7%
H
153.2
154.8
|
L
 4.0%
H
149.6
156.1
|
L
 -6.7%
H
145.3
163.1
|
L
 11.2%
H
135.6
170.5
|
L
 45.5%
H
97.7
170.5
|
L
 64.8%
H
92.2
170.5
|
L
 78.9%
H
74.1
170.5
|
L
 139.5%
H
59.2
170.5
|
| Organon & Co. |
|
1,655.6
|
6.4
|
L
 3.6%
H
6.0
6.4
|
L
 8.9%
H
5.7
6.4
|
L
 -7.4%
H
5.7
7.0
|
L
 -12.2%
H
5.7
9.9
|
L
 -51.3%
H
5.7
13.3
|
L
 -72.4%
H
5.7
24.8
|
L
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,483.3
|
52.5
|
L
 -9.0%
H
51.3
57.3
|
L
 -11.4%
H
51.3
60.4
|
L
 -24.0%
H
51.3
69.0
|
L
 -14.3%
H
51.3
71.1
|
L
 -36.7%
H
51.3
89.4
|
L
 -16.1%
H
51.3
90.0
|
L
 21.8%
H
42.7
90.0
|
L
 -2.2%
H
26.3
90.0
|
| Pfizer |
|
161,094.2
|
28.3
|
L
 -0.8%
H
28.2
28.7
|
L
 4.7%
H
27.2
28.7
|
L
 6.4%
H
26.2
28.7
|
L
 12.5%
H
25.0
28.7
|
L
 23.3%
H
20.9
28.7
|
L
 -30.8%
H
20.9
42.2
|
L
 -22.0%
H
20.9
61.7
|
L
 -2.7%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,493.5
|
10.9
|
L
 -1.4%
H
10.7
11.3
|
L
 13.9%
H
9.4
11.3
|
L
 -7.2%
H
9.2
11.7
|
L
 -21.9%
H
9.2
15.4
|
L
 -58.8%
H
9.2
28.4
|
L
 -69.7%
H
9.2
40.3
|
L
 -73.3%
H
9.2
50.9
|
L
 -91.6%
H
9.2
133.5
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,090.2
|
13.3
|
L
 -1.1%
H
13.0
13.4
|
L
 -1.2%
H
13.0
13.9
|
L
 -6.7%
H
13.0
14.6
|
L
 -3.9%
H
12.8
14.8
|
L
 7.8%
H
12.3
16.2
|
L
 15.8%
H
10.6
74.9
|
L
 6.2%
H
9.6
74.9
|
L
 46.9%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
59,203.3
|
18.7
|
L
 -0.2%
H
18.5
18.8
|
L
 4.6%
H
18.1
18.9
|
L
 2.9%
H
17.6
18.9
|
L
 20.0%
H
15.5
18.9
|
L
 27.3%
H
13.0
18.9
|
L
 12.4%
H
12.6
18.9
|
L
 0.5%
H
12.3
18.9
|
L
 -16.9%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
35,025.2
|
30.1
|
L
 -0.6%
H
29.4
30.4
|
L
 4.7%
H
28.3
30.7
|
L
 -8.6%
H
28.3
32.4
|
L
 -2.8%
H
28.3
37.3
|
L
 118.0%
H
12.5
37.3
|
L
 230.5%
H
7.1
37.3
|
L
 162.0%
H
6.8
37.3
|
L
 -45.0%
H
6.1
58.2
|
| Zoetis (Class A) |
|
49,785.7
|
117.9
|
L
 0.6%
H
115.4
118.6
|
L
 4.1%
H
113.6
118.9
|
L
 -6.4%
H
113.3
125.5
|
L
 -6.3%
H
113.3
132.5
|
L
 -22.3%
H
113.3
172.2
|
L
 -29.4%
H
113.3
201.9
|
L
 -25.3%
H
113.3
249.3
|
L
 157.7%
H
45.0
249.3
|
| Biohaven Ltd |
|
1,474.1
|
9.8
|
L
 1.9%
H
9.4
10.2
|
L
 17.1%
H
8.0
10.2
|
L
 -7.6%
H
8.0
12.1
|
L
 -9.6%
H
8.0
14.0
|
L
 -47.3%
H
7.5
24.1
|
L
 -28.3%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
275.0
|
4.8
|
L
 5.2%
H
4.5
4.8
|
L
 12.4%
H
4.2
4.8
|
L
 -3.0%
H
4.2
5.3
|
L
 -9.2%
H
4.2
5.7
|
L
 6.6%
H
3.9
7.5
|
L
 70.9%
H
2.7
9.0
|
L
 -89.6%
H
2.2
51
|
L
 -93.6%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
2,641.1
|
53.3
|
L
 5.7%
H
49
53.6
|
L
 19.9%
H
43.5
53.6
|
L
 52.4%
H
31.3
53.6
|
L
 88.6%
H
25.2
53.6
|
L
 580.8%
H
5.5
53.6
|
L
 123.2%
H
2.2
53.9
|
L
 18.2%
H
2.2
53.9
|
L
 -93.0%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
195.0
|
2.7
|
L
 5.9%
H
2.5
2.7
|
L
 19.5%
H
2.2
2.7
|
L
 -18.4%
H
2.2
3.6
|
L
 33.7%
H
1.7
3.6
|
L
 175.5%
H
0.9
3.6
|
L
 -29.7%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
875.7
|
4.5
|
L
 -0.9%
H
4.4
4.5
|
L
 4.4%
H
4.2
4.6
|
L
 -5.7%
H
4.1
4.9
|
L
 -6.1%
H
3.5
5
|
L
 38.7%
H
2.7
5.1
|
L
 49.8%
H
1.7
5.1
|
L
 30.6%
H
1.7
6.5
|
L
 8.0%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
27.9
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 9%
H
0.9
1.1
|
L
 -24.8%
H
0.9
1.5
|
L
 -50.2%
H
0.9
2.4
|
L
 47.3%
H
0.7
5.5
|
L
 -83.0%
H
0.4
9.6
|
L
 -97.6%
H
0.4
299.5
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,785.0
|
22.2
|
L
 -0.5%
H
21.7
22.5
|
L
 7.0%
H
20.7
22.9
|
L
 -5.1%
H
19.9
23.1
|
L
 -15.6%
H
19.9
27.8
|
L
 44.3%
H
13.4
28.4
|
L
 20.1%
H
13.4
33.9
|
L
 -13.2%
H
12.2
33.9
|
L
 -26.1%
H
12.2
58.7
|
| Adicet Bio Inc |
|
67.1
|
7.0
|
L
 1.6%
H
6.7
7.0
|
L
 8.0%
H
6.0
7.1
|
L
 -7.7%
H
6.0
8.1
|
L
 -20.8%
H
6.0
9.1
|
L
 -31.6%
H
6.0
17.4
|
L
 -91.8%
H
6.0
120
|
L
 -96.7%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
172.0
|
3.2
|
L
 2.9%
H
3.1
3.3
|
L
 21.9%
H
2.6
3.3
|
L
 -29.5%
H
2.6
4.6
|
L
 -35.0%
H
2.6
6.0
|
L
 48.2%
H
1.8
6.0
|
L
 -52.1%
H
1.8
10.3
|
L
 -72.0%
H
1.8
11.8
|
L
 -99.8%
H
1.8
3123.8
|
| AC Immune SA |
|
280.9
|
2.8
|
L
 -1.1%
H
2.7
2.8
|
L
 2.2%
H
2.6
2.9
|
L
 -2.8%
H
2.6
3.4
|
L
 -17.9%
H
2.4
3.9
|
L
 66.3%
H
1.4
4
|
L
 23.2%
H
1.4
5.1
|
L
 -64.1%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
508.6
|
4.2
|
L
 1.5%
H
4.0
4.2
|
L
 19.3%
H
3.3
4.2
|
L
 35.5%
H
3.0
4.2
|
L
 45.8%
H
2.5
4.9
|
L
 200%
H
1.1
4.9
|
L
 -51.6%
H
0.6
11.1
|
L
 -84.2%
H
0.6
30.4
|
L
 -79.5%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
58.9
|
1.5
|
L
 4.1%
H
1.4
1.5
|
L
 14.3%
H
1.3
1.5
|
L
 -10.1%
H
1.3
1.8
|
L
 -38.2%
H
1.3
3.6
|
L
 0.7%
H
1.1
3.6
|
L
 -87.0%
H
1.1
14.3
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
12.2
|
0.7
|
L
 -7.7%
H
0.7
0.8
|
L
 -2.7%
H
0.7
0.8
|
L
 -20.9%
H
0.7
0.9
|
L
 -37.9%
H
0.7
1.3
|
L
 44%
H
0.4
1.6
|
L
 20%
H
0.4
1.6
|
L
 -97.9%
H
0.4
34
|
L
 -98.9%
H
0.4
115
|
| Grace Therapeutics Inc |
|
79.4
|
5.1
|
L
 5.1%
H
4.7
5.2
|
L
 9.9%
H
4.3
5.2
|
L
 32.6%
H
3.6
5.2
|
L
 40.2%
H
3.4
5.2
|
L
 156.5%
H
1.8
5.2
|
L
 90%
H
1.7
5.2
|
L
 -82.3%
H
1.7
32.6
|
L
 -92.7%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
10.5
|
3.7
|
L
 -5.4%
H
3.5
3.8
|
L
 -2.1%
H
3.4
4.4
|
L
 142.1%
H
1.3
7.5
|
L
 33.3%
H
1.3
7.5
|
L
 -42.5%
H
1.3
21
|
L
 -94.7%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
2.4
|
1.7
|
L
 -2.3%
H
1.7
1.8
|
L
 3.1%
H
1.6
1.9
|
L
 -15.1%
H
1.5
2.1
|
L
 -71.7%
H
1.5
6.8
|
L
 -89.3%
H
1.5
30.3
|
L
 -99.2%
H
1.5
350
|
L
 -99.9%
H
1.5
3175
|
L
H
1.5
5900
|
| Agios Pharma Inc |
|
2,062.4
|
35.2
|
L
 3.0%
H
33.5
35.3
|
L
 19.6%
H
29.0
36.4
|
L
 24.9%
H
26.8
36.4
|
L
 29.5%
H
26.0
36.4
|
L
 36.7%
H
22.2
46
|
L
 63.0%
H
19.8
62.6
|
L
 -33.1%
H
16.8
62.6
|
L
 -19.6%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
369.7
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 3.0%
H
1.3
1.5
|
L
 10.4%
H
1.2
1.6
|
L
 -11.0%
H
1.1
1.6
|
L
 -22.0%
H
1.1
4.1
|
L
 155.6%
H
0.5
4.1
|
L
 -58.6%
H
0.2
4.3
|
L
 -85.5%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
49.3
|
8.0
|
L
 3.0%
H
7.3
8
|
L
 19.7%
H
6.4
8
|
L
 16.2%
H
6.4
8.1
|
L
 -12.7%
H
6.2
10.5
|
L
 34.0%
H
3.8
13.7
|
L
 -64.9%
H
3.8
46.3
|
L
 -98.6%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
5,806.1
|
34.8
|
L
 -0.6%
H
34.3
35.3
|
L
 18.5%
H
29.1
36.5
|
L
 19.0%
H
27
36.5
|
L
 23.3%
H
27
36.5
|
L
 15.9%
H
25.2
36.5
|
L
 19.7%
H
22.0
36.5
|
L
 81.9%
H
18.4
36.5
|
L
 -4.2%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
18.7
|
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 8.4%
H
1.0
1.2
|
L
 10.5%
H
1.0
1.4
|
L
 1.8%
H
0.8
1.4
|
L
 46.8%
H
0.6
2.1
|
L
 -99.9%
H
0.1
3088
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
42,286.9
|
318.9
|
L
 -3.0%
H
315.9
325.5
|
L
 0.5%
H
314.2
335.5
|
L
 -2.6%
H
299.6
335.5
|
L
 -20.3%
H
298
427.1
|
L
 35.3%
H
205.9
495.6
|
L
 57.3%
H
142.0
495.6
|
L
 124.8%
H
117.6
495.6
|
L
 372.1%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
33.9
|
1.2
|
L
H
1.1
1.3
|
L
 -3.2%
H
1.1
1.3
|
L
 0.8%
H
1.1
1.5
|
L
 -3.2%
H
1.1
1.6
|
L
 -28.8%
H
1.0
2.4
|
L
 0.8%
H
1.0
7.4
|
L
 -95.8%
H
1.0
29
|
L
H
1.0
309.6
|
| Alzamend Neuro Inc |
|
3.8
|
1
|
L
 -2.0%
H
1.0
1.0
|
L
 -4.8%
H
1.0
1.1
|
L
 -49.5%
H
1.0
2.4
|
L
 -47.4%
H
1.0
2.5
|
L
 -88.7%
H
1.0
8.8
|
L
 -99.9%
H
1.0
1071.9
|
L
H
1.0
45292.5
|
L
H
1.0
45292.5
|
| Amylyx Pharma Inc |
|
1,652.5
|
15.0
|
L
 4.2%
H
13.9
15.2
|
L
 10.3%
H
12.7
15.2
|
L
 -0.7%
H
12.7
15.3
|
L
 30.9%
H
10.8
17.5
|
L
 335.9%
H
3.1
17.5
|
L
 -47.8%
H
1.6
31.8
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
927.8
|
20.5
|
L
 1.0%
H
19.9
20.7
|
L
 7.6%
H
19.1
20.7
|
L
 2.5%
H
17.0
20.7
|
L
 -22.7%
H
17.0
29.5
|
L
 -23.2%
H
17.0
31.3
|
L
 -47.2%
H
17.0
67.7
|
L
 13.0%
H
16.9
67.7
|
L
 58.7%
H
11.4
67.7
|
| Annexon Inc |
|
882.6
|
5.5
|
L
 2.6%
H
5.1
5.7
|
L
 10%
H
4.9
6.1
|
L
 -1.6%
H
4.9
6.3
|
L
 17.3%
H
4.5
7.2
|
L
 225.4%
H
1.3
7.2
|
L
 38.5%
H
1.3
8.4
|
L
 -80.0%
H
1.3
28.0
|
L
H
1.3
38.0
|
| Apollomics Inc (Class A) |
|
31.6
|
14.7
|
L
H
14.5
15.1
|
L
 -14.7%
H
14.5
17.6
|
L
 -28.2%
H
14.5
20.8
|
L
 -23.7%
H
14.5
23.0
|
L
 145.3%
H
3.7
42.1
|
L
 -99.2%
H
0.1
2129
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
5,166.1
|
40.4
|
L
 0.1%
H
40.4
40.5
|
L
 138.1%
H
16.8
40.5
|
L
 103.5%
H
16.8
40.5
|
L
 56.3%
H
16.8
40.5
|
L
 102.4%
H
16.1
40.5
|
L
 -48.2%
H
16.1
94.8
|
L
 -6.7%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Aptorum Grp Ltd (Class A) |
|
7.5
|
0.9
|
L
 -3.2%
H
0.9
1.0
|
L
 -1.1%
H
0.8
1.0
|
L
 10.8%
H
0.8
1.3
|
L
 -14.0%
H
0.7
1.3
|
L
 22.7%
H
0.7
4.5
|
L
 -66.1%
H
0.5
17.5
|
L
 -97.0%
H
0.5
35.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
8.2
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 5.9%
H
0.6
0.8
|
L
 -20.9%
H
0.6
1.0
|
L
 -15.3%
H
0.6
1.5
|
L
 -57.7%
H
0.6
2.2
|
L
 -81.9%
H
0.6
8.9
|
L
 -99.3%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
504.0
|
4.1
|
L
H
4.0
4.2
|
L
 2.7%
H
3.9
4.2
|
L
 -5.5%
H
3.8
4.5
|
L
 -36.0%
H
2.9
6.5
|
L
 52.4%
H
2.1
7.6
|
L
 275.5%
H
1.1
7.6
|
L
 -19.6%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
228.2
|
8.0
|
L
 2.3%
H
7.5
8.3
|
L
 18.8%
H
6.8
8.3
|
L
 5.9%
H
6.4
8.3
|
L
 28.5%
H
6.1
8.7
|
L
 -11.9%
H
5.9
24.2
|
L
 -70.3%
H
5.9
45
|
L
 -80.2%
H
5.9
65
|
L
 -72.8%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,456.8
|
5.9
|
L
 -2.8%
H
5.8
6.0
|
L
 8.4%
H
5.4
6.2
|
L
 -10.7%
H
5.1
6.7
|
L
 -3.4%
H
5.1
8.4
|
L
 30.6%
H
3.2
8.4
|
L
 31.7%
H
3.2
10.1
|
L
 -13.4%
H
0.5
10.1
|
L
 -24.1%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,930.9
|
23.6
|
L
 -2.0%
H
23.2
24.1
|
L
 11.4%
H
21.1
24.5
|
L
 -2.0%
H
21.1
25.5
|
L
 -18.5%
H
21.1
30.8
|
L
 60.4%
H
11.9
31.8
|
L
 119.2%
H
1.8
31.8
|
L
 -20.5%
H
1.8
36.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
5.8
|
7.0
|
L
 -10.2%
H
7
8.1
|
L
 -33.2%
H
7
10.6
|
L
 95.6%
H
3.0
19.9
|
L
 84.8%
H
3.0
19.9
|
L
 -57.4%
H
3.0
85.8
|
L
 -84.2%
H
3.0
85.8
|
L
 -98.4%
H
3.0
475.2
|
L
H
3.0
46656
|
| Assembly Biosciences Inc |
|
460.2
|
29.0
|
L
 -1.4%
H
28.4
29.8
|
L
 4.7%
H
26.3
30.0
|
L
 -2.6%
H
26.3
30.2
|
L
 -14.0%
H
24.7
33.7
|
L
 233.1%
H
7.8
39.7
|
L
 198.5%
H
7.7
39.7
|
L
 -47.0%
H
7.7
56.3
|
L
 -52.9%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
536.7
|
4.3
|
L
 4.4%
H
3.9
4.3
|
L
 -1.8%
H
3.9
4.5
|
L
 -19.2%
H
3.9
6.5
|
L
 -23.8%
H
3.9
8.6
|
L
 -2.7%
H
3.9
14.5
|
L
 356.4%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
123.8
|
19.2
|
L
 -3.4%
H
18.8
20.2
|
L
 -0.9%
H
17.9
20.2
|
L
 59.2%
H
11.1
20.5
|
L
 110.2%
H
9.1
20.5
|
L
 104.4%
H
7.7
20.5
|
L
 -78.5%
H
7.7
120.2
|
L
 -55.2%
H
7.7
120.2
|
L
 -97.8%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,376.6
|
3.8
|
L
 2.4%
H
3.5
3.8
|
L
 13.1%
H
3.4
3.8
|
L
 2.7%
H
3.3
4.3
|
L
 -2.1%
H
3.3
4.4
|
L
 189.3%
H
1.2
6.8
|
L
 115.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
55.9
|
2.8
|
L
 -2.1%
H
2.5
2.8
|
L
 2.6%
H
2.5
3.1
|
L
 -16.4%
H
2.5
3.4
|
L
 -46.2%
H
2.5
5.7
|
L
 -68.2%
H
2.5
174.6
|
L
 -99.2%
H
2.5
513
|
L
 -100.0%
H
2.5
49571
|
L
H
2.5
49571
|
| Atossa Therapeutics Inc |
|
46.2
|
5.4
|
L
 4.9%
H
5
5.6
|
L
 13.6%
H
4.6
5.6
|
L
 8.9%
H
4.4
6.1
|
L
 -43.3%
H
3.8
11.0
|
L
 -40.6%
H
3.8
19.4
|
L
 -50.4%
H
3.8
34.7
|
L
 -83.5%
H
3.8
147
|
L
 -99.3%
H
3.8
1107
|
| Atara Biotherapeutics Inc |
|
40.8
|
5.0
|
L
 -3.5%
H
4.9
5.3
|
L
 8.7%
H
4.3
5.3
|
L
 -7.4%
H
4.3
7.3
|
L
 -71.9%
H
3.9
19.1
|
L
 -10.7%
H
3.9
19.1
|
L
 -93.0%
H
0.4
77
|
L
 -98.7%
H
0.4
501
|
L
 -99.0%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
458.9
|
5.8
|
L
 2.0%
H
5.5
5.8
|
L
 12.5%
H
5.0
5.8
|
L
 15.7%
H
4.8
6.5
|
L
 65.5%
H
3.3
6.5
|
L
 106.5%
H
2.5
6.5
|
L
 71.4%
H
2.5
6.5
|
L
 -90.0%
H
2.5
62.0
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
404.7
|
17.8
|
L
 6.4%
H
16.1
17.8
|
L
 27.9%
H
13.5
17.8
|
L
 -3.3%
H
13.1
18.5
|
L
 4.4%
H
13.0
19.1
|
L
 206.2%
H
3.4
20.7
|
L
 875.8%
H
0.0
34.5
|
L
 -51.5%
H
0.0
44.4
|
L
 -60.7%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
28.8
|
2.7
|
L
 1.5%
H
2.6
2.7
|
L
 3.1%
H
2.5
2.8
|
L
 3.1%
H
2.4
2.8
|
L
 -3.3%
H
2.1
3.1
|
L
 160.2%
H
1.0
3.1
|
L
 19.1%
H
1.0
3.5
|
L
 -98.2%
H
1.0
151
|
L
 -100.0%
H
1.0
604896
|
| Adagene Inc (ADR) |
|
188.1
|
4.0
|
L
 -13.5%
H
3.8
4.6
|
L
 5.8%
H
3.6
4.7
|
L
 36.2%
H
2.8
4.7
|
L
 116.9%
H
1.5
4.7
|
L
 152.5%
H
1.3
4.7
|
L
 191.2%
H
1.1
4.7
|
L
 -77.4%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.0
|
5.7
|
L
 -8.9%
H
5.7
6.5
|
L
 -14.6%
H
5.7
7.0
|
L
 -19.7%
H
5.6
7.3
|
L
 -29.3%
H
5.6
10.4
|
L
 -23.0%
H
5.6
12.1
|
L
 -69.0%
H
5
27.9
|
L
 -97.3%
H
5
229.6
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
306.7
|
14.7
|
L
 0.7%
H
14.5
14.9
|
L
 2.0%
H
13.8
14.9
|
L
 1.4%
H
13.7
17
|
L
 7.4%
H
13.1
17.3
|
L
 3585%
H
0.4
20.9
|
L
 930.8%
H
0.4
20.9
|
L
 127.5%
H
0.4
20.9
|
L
 821.3%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
14,074.4
|
229.3
|
L
 0.4%
H
223.8
229.5
|
L
 5.7%
H
215.0
235.6
|
L
 -5.0%
H
212.6
245.6
|
L
 7.5%
H
188.1
248.6
|
L
 60.7%
H
124.1
248.6
|
L
 220.9%
H
66.0
248.6
|
L
 75.8%
H
61.6
248.6
|
L
 1130.5%
H
11.9
248.6
|
| Alterity Therapeutics Ltd (ADR) |
|
64.5
|
3.6
|
L
 -2.2%
H
3.5
3.6
|
L
 12.7%
H
3.3
3.7
|
L
 4.7%
H
3.1
3.7
|
L
 12.7%
H
3.0
3.8
|
L
 22.8%
H
2.5
7
|
L
 27.1%
H
1
7
|
L
 -76.3%
H
1
27.5
|
L
 -87.6%
H
1
66.9
|
| Astrazeneca plc |
|
630,934.4
|
203.5
|
L
 1.4%
H
199.2
204.3
|
L
 8%
H
192.6
204.3
|
L
 1.0%
H
182.4
204.3
|
L
 8%
H
182.4
212.7
|
L
 8%
H
182.4
212.7
|
L
 8.0%
H
182.4
212.7
|
L
 8.0%
H
182.4
212.7
|
L
 8.0%
H
182.4
212.7
|
| Biofrontera Inc |
|
11.4
|
1.0
|
L
 6.5%
H
0.9
1.0
|
L
 19.5%
H
0.8
1.0
|
L
 8.9%
H
0.8
1.0
|
L
 36.1%
H
0.7
1.0
|
L
 32.4%
H
0.5
1.2
|
L
 -92.4%
H
0.5
13.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
111.3
|
1.5
|
L
 3.4%
H
1.4
1.5
|
L
 16.7%
H
1.3
1.6
|
L
 10.8%
H
1.1
1.6
|
L
 14.9%
H
1.0
1.7
|
L
 -27.4%
H
0.9
3.1
|
L
 -94.2%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
8.2
|
4.3
|
L
 -4.9%
H
4.3
4.7
|
L
 -2.1%
H
4.0
4.7
|
L
 -3.8%
H
3.9
4.9
|
L
 -25.9%
H
3.9
7.2
|
L
 -40.4%
H
3.9
9.2
|
L
 -84.8%
H
3.9
40.6
|
L
 -99.3%
H
3.9
638.2
|
L
H
3.9
861.4
|
| Blue Water Biotech Inc |
|
27.1
|
1.5
|
L
 -19.2%
H
1.3
1.7
|
L
 -21.7%
H
1.2
1.9
|
L
 123.5%
H
0.4
6.7
|
L
 -5.6%
H
0.4
6.7
|
L
 1800%
H
0.1
6.7
|
L
 47.6%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
70.7
|
1.7
|
L
 0.6%
H
1.7
1.7
|
L
 7.5%
H
1.5
1.8
|
L
 11.7%
H
1.3
1.9
|
L
 6.8%
H
1.2
1.9
|
L
 28.4%
H
1.0
3.4
|
L
 53.6%
H
0.7
4
|
L
 -84.1%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharma PLC (ADR) |
|
2.8
|
0.9
|
L
 42.6%
H
0.8
1.4
|
L
 33.9%
H
0.6
1.4
|
L
 -7.5%
H
0.6
1.4
|
L
 -64.6%
H
0.6
2.6
|
L
 -94.9%
H
0.6
19.3
|
L
 -100.0%
H
0.6
175010.9
|
L
 -100.0%
H
0.6
36100000
|
L
 -100.0%
H
0.6
2640000000
|
| BeiGene Ltd (ADR) |
|
33,107.3
|
310.8
|
L
 0.8%
H
306.3
316.0
|
L
 9.8%
H
281.1
316.0
|
L
 3.9%
H
271.5
316.0
|
L
 -0.1%
H
271.5
372.7
|
L
 36.1%
H
228.9
385.2
|
L
 44.6%
H
127.0
385.2
|
L
 -9.2%
H
118.2
426.6
|
L
 937.0%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
9.6
|
2.2
|
L
 1.4%
H
2.2
2.3
|
L
 -6.8%
H
2.2
2.4
|
L
 -21.4%
H
2.2
2.9
|
L
 -21.1%
H
2.2
3.2
|
L
 -16.6%
H
2.2
7.8
|
L
 -94.3%
H
0.1
101.2
|
L
 -98.1%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,788.1
|
169.9
|
L
 1.6%
H
162
176.2
|
L
 11.7%
H
147
176.2
|
L
 -4.5%
H
146.6
182.0
|
L
 6.6%
H
146.1
200
|
L
 198.5%
H
49
200
|
L
 466.2%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
23.8
|
4.4
|
L
 7.0%
H
4.1
4.5
|
L
 7.6%
H
3.8
4.5
|
L
 -5.0%
H
3.8
4.9
|
L
 15.5%
H
3.8
4.9
|
L
 -14.5%
H
3.6
21.4
|
L
 125%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,846.7
|
32.1
|
L
 6.6%
H
28.9
32.4
|
L
 11.1%
H
27.5
32.4
|
L
 25.9%
H
25.1
36.5
|
L
 13.4%
H
21.1
36.5
|
L
 254.4%
H
4.3
40.4
|
L
 670.0%
H
2.7
40.4
|
L
 564.8%
H
2.6
40.4
|
L
 17.2%
H
0.9
54
|
| Cullinan Oncology Inc |
|
873.4
|
14.4
|
L
 3.5%
H
13.5
14.6
|
L
 12.3%
H
12.6
14.8
|
L
 -11.5%
H
12.4
16.6
|
L
 42.6%
H
9.4
16.7
|
L
 94.7%
H
5.7
16.7
|
L
 38.6%
H
5.7
30.2
|
L
 -65.0%
H
5.7
42
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
259.3
|
1.7
|
L
 -0.6%
H
1.7
1.8
|
L
 6.1%
H
1.6
1.8
|
L
 -1.7%
H
1.5
2.1
|
L
 26.3%
H
1.4
2.6
|
L
 121.8%
H
0.7
2.6
|
L
 -76.8%
H
0.7
8.7
|
L
 -88.1%
H
0.7
19.3
|
L
 -92.2%
H
0.7
32.0
|
| Cingulate Inc |
|
71.4
|
6.1
|
L
 2.2%
H
5.6
6.4
|
L
 -3.9%
H
5.6
6.8
|
L
 -8.6%
H
5.6
11.9
|
L
 40.2%
H
4.3
11.9
|
L
 62.4%
H
3.2
11.9
|
L
 520.2%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
60.3
|
5.1
|
L
 4.7%
H
4.5
5.2
|
L
 8.7%
H
4.5
5.4
|
L
 -7.1%
H
4.5
6.7
|
L
 -11.3%
H
3.9
6.7
|
L
 90.3%
H
2.3
13.5
|
L
 -79.0%
H
2.3
24.4
|
L
 -98.0%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
10.8
|
2.6
|
L
 2%
H
2.4
2.6
|
L
 -5.6%
H
2.4
2.8
|
L
 -12.1%
H
2.4
3.5
|
L
 -26.5%
H
2.4
4.1
|
L
 -67.8%
H
2.4
20.6
|
L
 -94.0%
H
2.4
133.5
|
L
 -99.5%
H
2.4
552
|
L
 -100.0%
H
2.4
14790
|
| Clearmind Medicine Inc |
|
2.6
|
1.1
|
L
H
1.1
1.1
|
L
 33.3%
H
0.8
1.1
|
L
 -9.2%
H
0.6
1.2
|
L
 -45.7%
H
0.6
2.8
|
L
 -97.4%
H
0.6
52.4
|
L
 -99.8%
H
0.6
986.4
|
L
 -100.0%
H
0.6
788400
|
L
H
0.6
788400
|
| Compass Therapeutics Inc |
|
981.5
|
5.5
|
L
 0.4%
H
5.2
5.5
|
L
 4.6%
H
5.1
5.5
|
L
 -4.2%
H
4.9
5.9
|
L
 5.4%
H
4.8
6.9
|
L
 273.3%
H
1.4
6.9
|
L
 75.2%
H
0.8
6.9
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
1.4
|
2.3
|
L
 -0.9%
H
2.2
2.3
|
L
 -7.4%
H
2.2
2.7
|
L
 -26.6%
H
2.1
3.6
|
L
 -57.4%
H
2.1
8.9
|
L
 -82.9%
H
2.1
34.8
|
L
 -100.0%
H
2.1
6600000
|
L
 -100.0%
H
2.1
120600000
|
L
H
2.1
256050000
|
| Context Therapeutics Inc |
|
249.9
|
2.7
|
L
 2.6%
H
2.6
3.0
|
L
 5.0%
H
2.5
3.0
|
L
 4.6%
H
2.5
3.6
|
L
 75.5%
H
1.4
3.6
|
L
 353.3%
H
0.5
3.6
|
L
 338.7%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
20.8
|
1.5
|
L
 48.0%
H
1.4
2.0
|
L
 46.6%
H
1
2.0
|
L
 46.6%
H
1.0
2.0
|
L
 52.5%
H
0.9
2.0
|
L
 6.3%
H
0.9
2.7
|
L
 -26.3%
H
0.9
3.3
|
L
 -91.2%
H
0.9
41.5
|
L
 -99.4%
H
0.9
309.6
|
| Collegium pharma Inc |
|
1,025.9
|
32.3
|
L
 -2.8%
H
32.1
33.3
|
L
 -0.4%
H
31.8
34.0
|
L
 -18.4%
H
31.8
39.4
|
L
 -29.0%
H
31.8
49.3
|
L
 14.8%
H
23.2
50.8
|
L
 34.6%
H
20.8
50.8
|
L
 38.2%
H
14.0
50.8
|
L
 67.8%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
4,519.8
|
42.5
|
L
 1.2%
H
40.5
43.4
|
L
 13.0%
H
37.5
43.4
|
L
 19.1%
H
31.8
50.4
|
L
 11.2%
H
28.7
50.4
|
L
 -42.9%
H
28.7
91
|
L
 93.0%
H
20.8
117.3
|
L
 73.9%
H
15.8
117.3
|
L
 807.9%
H
4.6
117.3
|
| Cosmos Health Inc |
|
11.6
|
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
 -20.5%
H
0.3
0.4
|
L
 -40.4%
H
0.3
0.6
|
L
 -11.4%
H
0.3
1.3
|
L
 -90.5%
H
0.3
4.1
|
L
 -99.8%
H
0.3
194.3
|
L
 -99.8%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
47.4
|
3.2
|
L
 2.3%
H
3
3.2
|
L
 3.3%
H
3
3.3
|
L
 -13.6%
H
2.7
3.9
|
L
 -20.4%
H
2.7
5.4
|
L
 -25.1%
H
1.9
6.3
|
L
 66.8%
H
1.0
7.3
|
L
 3.3%
H
1.0
7.5
|
L
 -32.1%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
3,015.2
|
24.7
|
L
 -0.5%
H
24.4
24.8
|
L
 5.5%
H
23.1
25.1
|
L
H
22.2
25.4
|
L
 6.7%
H
22.1
25.5
|
L
 7.0%
H
19.1
26.6
|
L
 47.1%
H
11.1
26.6
|
L
 447.5%
H
4.2
26.6
|
L
 1957.5%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
180.4
|
10.2
|
L
 1.9%
H
9.9
10.5
|
L
 16.8%
H
8.4
10.5
|
L
 20.8%
H
7.7
10.5
|
L
 29.2%
H
7.2
10.5
|
L
 102.6%
H
4.6
20.6
|
L
 46.5%
H
3.0
61.9
|
L
 -83.5%
H
2.1
68.7
|
L
 -81.6%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
3,898.2
|
37.2
|
L
 1.8%
H
35.8
37.3
|
L
 10.6%
H
33.1
37.5
|
L
 -5.8%
H
33.1
39.9
|
L
 -20.3%
H
33.1
58.0
|
L
 38.5%
H
24.1
58.0
|
L
 129.1%
H
15.5
62.5
|
L
 132.7%
H
15.2
62.5
|
L
H
10.6
62.5
|
| Corvus Pharma Inc |
|
1,233.8
|
14.7
|
L
 1.8%
H
13.9
14.8
|
L
 4.9%
H
13.2
15.4
|
L
 -17.7%
H
13.0
17.6
|
L
 100.7%
H
6.4
27.0
|
L
 415.4%
H
2.5
27.0
|
L
 1260.2%
H
1.0
27.0
|
L
 367.8%
H
0.6
27.0
|
L
 2.0%
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
985.8
|
4.6
|
L
H
4.3
4.6
|
L
 0.9%
H
4.3
4.9
|
L
 -10.1%
H
4.1
8.2
|
L
 7.3%
H
4.0
8.2
|
L
 891.3%
H
0.4
8.2
|
L
 206.0%
H
0.4
8.2
|
L
 -42.1%
H
0.4
10.1
|
L
 -66.5%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
4.9
|
1
|
L
 1.0%
H
1.0
1.0
|
L
H
0.9
1.0
|
L
 4.2%
H
0.7
1.2
|
L
 -29.1%
H
0.7
1.7
|
L
 -98.1%
H
0.7
100.8
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
28620
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
23.4
|
6.2
|
L
 -3.6%
H
4.7
6.8
|
L
 310%
H
1.4
8.5
|
L
 342.5%
H
1.3
8.5
|
L
 359.0%
H
1.0
8.5
|
L
 146%
H
1.0
8.5
|
L
 -7.7%
H
1.0
8.5
|
L
 -90.7%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
8,218.7
|
66.7
|
L
 0.2%
H
65.4
68.7
|
L
 6.8%
H
61.7
68.7
|
L
 7.2%
H
58.4
68.7
|
L
 8.1%
H
58.4
70.4
|
L
 78.6%
H
29.3
71.0
|
L
 83.7%
H
26.0
110
|
L
 173.0%
H
17.7
110
|
L
 786.2%
H
5.8
110
|
| Cellectis (ADR) |
|
343.0
|
3.4
|
L
 0.9%
H
3.4
3.5
|
L
 10.7%
H
3.0
3.5
|
L
 -9.1%
H
3.0
4.0
|
L
 -29.0%
H
3.0
4.9
|
L
 196.5%
H
1.1
5.5
|
L
 73.1%
H
1.0
5.5
|
L
 -82.7%
H
1.0
21.2
|
L
 -87.8%
H
1.0
38.9
|
| Centessa Pharma PLC (ADR) |
|
6,138.5
|
39.7
|
L
 -0.4%
H
39.7
39.8
|
L
 38.3%
H
27.3
40.3
|
L
 48.7%
H
25.1
40.3
|
L
 67.5%
H
21.5
40.3
|
L
 239.8%
H
9.6
40.3
|
L
 950%
H
3.5
40.3
|
L
H
2.9
40.3
|
L
H
2.9
40.3
|
| Connect Biopharma Holdings Ltd (ADR) |
|
166.6
|
3.0
|
L
 9.9%
H
2.7
3.0
|
L
 -13.3%
H
2.6
3.6
|
L
 15.4%
H
2.5
3.8
|
L
 18.7%
H
2.0
3.8
|
L
 374.6%
H
0.5
3.8
|
L
 176.9%
H
0.5
3.8
|
L
 -83.2%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
25.3
|
1.7
|
L
 -8.4%
H
1.7
1.9
|
L
 12.3%
H
1.5
1.9
|
L
 11.5%
H
1.3
1.9
|
L
 -10.8%
H
1.3
2.1
|
L
 -40%
H
1.3
9.2
|
L
 -86.1%
H
0.3
13.2
|
L
 -91.5%
H
0.3
30.1
|
L
 -99.5%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
2,215.7
|
21.5
|
L
 0.1%
H
21.4
21.5
|
L
 0.2%
H
21.4
21.5
|
L
 66.7%
H
12.5
21.5
|
L
 142.4%
H
8.4
21.5
|
L
 197.1%
H
5.6
21.5
|
L
 70.0%
H
5.6
21.5
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
135.3
|
5.0
|
L
 6.7%
H
4.5
5.0
|
L
 8.1%
H
4.3
5.0
|
L
 -38.4%
H
4.3
8.5
|
L
 -33.6%
H
4.3
9.6
|
L
 -31.2%
H
4.3
9.6
|
L
 203.7%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
4.1
|
L
 3.5%
H
3.9
4.4
|
L
 11.3%
H
3.5
4.4
|
L
 3.0%
H
3.5
5.1
|
L
 -46.9%
H
3.5
8.2
|
L
 -52.9%
H
3.5
13.1
|
L
 -28.4%
H
3.5
14.4
|
L
 -94.0%
H
3.5
69
|
L
 -100.0%
H
3.5
17437.5
|
| DiaMedica Therapeutics Inc |
|
349.2
|
6.5
|
L
 0.9%
H
6.2
6.5
|
L
 -4.6%
H
6.1
7.5
|
L
 -16.6%
H
6.1
8.1
|
L
 -18.3%
H
6.1
9.0
|
L
 85.1%
H
3.2
10.4
|
L
 297.5%
H
1.5
10.4
|
L
 -33.4%
H
1.1
10.4
|
L
 143.6%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
5.2
|
1.3
|
L
 7.5%
H
1.2
1.3
|
L
 9.3%
H
1.1
1.3
|
L
 9.3%
H
1.1
1.8
|
L
 -40.8%
H
1.1
4.7
|
L
 34.4%
H
0.6
7.1
|
L
 7.5%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
1,246.9
|
21.1
|
L
 2.7%
H
19.8
21.3
|
L
 5.3%
H
19.1
21.8
|
L
 -7.6%
H
18.6
24.1
|
L
 10.6%
H
16.5
25.4
|
L
 224%
H
6.5
26.2
|
L
 21.4%
H
0.5
26.2
|
L
 -60.4%
H
0.5
68.8
|
L
 -93.7%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
51.3
|
6.1
|
L
 10.6%
H
5.3
6.3
|
L
 5.5%
H
5.0
6.3
|
L
 43.8%
H
3.6
9.4
|
L
 309.3%
H
0.7
9.4
|
L
 165.8%
H
0.7
9.4
|
L
 -8.6%
H
0.7
9.4
|
L
 -84.3%
H
0.7
84
|
L
 -99.5%
H
0.7
1669.9
|
| Eledon Pharma Inc |
|
232.9
|
3.1
|
L
 2.3%
H
2.9
3.1
|
L
 8.5%
H
2.7
3.2
|
L
 22.3%
H
2.5
3.2
|
L
 89.5%
H
1.6
3.2
|
L
 8.5%
H
1.4
4.6
|
L
 57.4%
H
1.1
5.4
|
L
 -73.9%
H
1.1
11.9
|
L
 -99.7%
H
1.1
1425.6
|
| Enanta Pharma Inc |
|
381.3
|
13.1
|
L
 1.3%
H
12.6
13.3
|
L
 7.9%
H
11.8
13.3
|
L
 -14.7%
H
11.8
15.5
|
L
 -8.9%
H
11.8
15.7
|
L
 177.8%
H
4.1
17.2
|
L
 -66.2%
H
4.1
40.0
|
L
 -74.1%
H
4.1
102
|
L
 -55.3%
H
4.1
127.8
|
| Entera Bio Ltd |
|
58.7
|
1.3
|
L
 10.5%
H
1.2
1.4
|
L
 11.5%
H
0.9
1.4
|
L
 -3.1%
H
0.9
1.6
|
L
 -28.8%
H
0.9
1.8
|
L
 -21.3%
H
0.9
3.2
|
L
 28.6%
H
0.5
3.4
|
L
 -67.7%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Evolus Inc |
|
262.2
|
4.0
|
L
 -6.5%
H
4.0
4.2
|
L
 0.5%
H
3.9
4.4
|
L
 -27.9%
H
3.9
6.3
|
L
 -40.0%
H
3.9
6.7
|
L
 -62.3%
H
3.9
12.3
|
L
 -51.9%
H
3.9
17.8
|
L
 -68.0%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
5,535.3
|
17.8
|
L
 7.3%
H
16.3
18.2
|
L
 19.0%
H
14.5
18.2
|
L
 17.8%
H
12.9
18.2
|
L
 396.1%
H
3.4
18.2
|
L
 1435.3%
H
1.0
18.2
|
L
 509.9%
H
1.0
18.2
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
670.3
|
2.6
|
L
H
2.5
2.7
|
L
 -4.7%
H
2.5
2.9
|
L
 -10.3%
H
2.4
3.3
|
L
 -29.7%
H
2.4
4.2
|
L
 112.2%
H
0.7
4.2
|
L
 90.5%
H
0.7
4.2
|
L
 -90.9%
H
0.7
29.3
|
L
 -86.5%
H
0.7
82.7
|
| Eton Pharma Inc |
|
681.8
|
25.0
|
L
 -1.5%
H
24.1
25.6
|
L
 7.5%
H
22.4
26.0
|
L
 42.6%
H
16.1
26.0
|
L
 53.7%
H
14.3
26.0
|
L
 111.2%
H
11.1
26.0
|
L
 582.8%
H
2.4
26.0
|
L
 241.9%
H
2.0
26.0
|
L
H
2.0
26.0
|
| Exelixis Inc |
|
11,396.0
|
43.9
|
L
 -0.4%
H
43.3
43.9
|
L
 5.7%
H
41.6
44.2
|
L
 5.3%
H
40.2
44.2
|
L
 0.7%
H
39.7
46.3
|
L
 26.9%
H
32.4
49.6
|
L
 124.5%
H
18.1
49.6
|
L
 89.8%
H
14.9
49.6
|
L
 930.0%
H
4.1
49.6
|
| Hyperion DeFi Inc |
|
37.0
|
3.3
|
L
 -0.6%
H
2.9
3.3
|
L
 -5.0%
H
2.9
3.5
|
L
 1.3%
H
2.9
4.0
|
L
 -9.2%
H
2.8
4.5
|
L
 238.5%
H
0.9
17.2
|
L
 -98.9%
H
0.0
468
|
L
 -99.2%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,118.0
|
13.4
|
L
 2.9%
H
12.6
13.6
|
L
 7.2%
H
11.8
13.7
|
L
 -25.6%
H
11.8
18.0
|
L
 -23.3%
H
11.8
18.9
|
L
 190.7%
H
3.9
19.1
|
L
 312.3%
H
2.9
31.0
|
L
 24.0%
H
2.2
31.0
|
L
 -54.7%
H
2.2
42.5
|
| Evotec SE (ADR) |
|
920.7
|
2.6
|
L
 2.0%
H
2.5
2.6
|
L
 7.0%
H
2.3
2.6
|
L
 -20.8%
H
2.3
3.2
|
L
 -18.6%
H
2.3
3.9
|
L
 -15.4%
H
2.3
4.8
|
L
 -76.2%
H
2.3
13.5
|
L
 -86.0%
H
2.3
26.6
|
L
 45.5%
H
1.9
26.6
|
| Fortress Biotech Inc |
|
83.7
|
2.6
|
L
 5.3%
H
2.4
2.6
|
L
 -5.8%
H
2.4
2.9
|
L
 -16.1%
H
2.4
3.5
|
L
 -35.5%
H
2.4
4.5
|
L
 71.1%
H
1.3
4.5
|
L
 -76.9%
H
1.2
12.8
|
L
 -95.5%
H
1.2
91.5
|
L
 -94.8%
H
1.2
91.5
|
| Fennec Pharma Inc |
|
221.3
|
6.4
|
L
 0.2%
H
6.3
6.6
|
L
 8.6%
H
5.7
6.6
|
L
 -21.7%
H
5.7
8.7
|
L
 -16.4%
H
5.7
9.2
|
L
 22.3%
H
4.7
9.9
|
L
 -23.5%
H
4.0
11.9
|
L
 2.6%
H
3.8
11.9
|
L
 252.7%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.4
|
7.0
|
L
 -1.3%
H
7.0
7.4
|
L
 6.4%
H
6.3
7.4
|
L
 1.3%
H
6.3
7.7
|
L
 -23.5%
H
6.3
9.8
|
L
 0.1%
H
4.9
12.6
|
L
 -98.5%
H
4.5
522.5
|
L
 -99.2%
H
4.5
901.5
|
L
 -98.7%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
93.3
|
6.4
|
L
 4.4%
H
5.8
6.6
|
L
 -12%
H
5.7
7.5
|
L
 34.9%
H
4.2
8.0
|
L
 85.5%
H
3.2
8.0
|
L
 289.0%
H
1.3
8.0
|
L
 -64.9%
H
1.3
53.8
|
L
 -96.3%
H
1.3
176.9
|
L
H
1.3
572.4
|
| Amicus Therapeutics Inc |
|
4,534.2
|
14.4
|
L
H
14.4
14.4
|
L
 0.2%
H
14.4
14.5
|
L
 0.8%
H
14.3
14.5
|
L
 1.2%
H
14.2
14.5
|
L
 92.5%
H
5.5
14.5
|
L
 32.1%
H
5.5
14.6
|
L
 43.5%
H
5.5
14.6
|
L
 75.0%
H
4.4
25.4
|
| Fulcrum Therapeutics Inc |
|
535.5
|
8.0
|
L
 7.5%
H
7.3
8.1
|
L
 19.5%
H
6.5
8.1
|
L
 -3.7%
H
6.5
8.5
|
L
 -26.4%
H
6.5
12.0
|
L
 220.3%
H
2.3
15.7
|
L
 206.9%
H
2.3
15.7
|
L
 -33%
H
2.3
33.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
903.8
|
14.6
|
L
 -1.0%
H
14.2
14.8
|
L
 10.8%
H
12.8
15.5
|
L
 -8.9%
H
12.8
16.5
|
L
 10.1%
H
12.8
19
|
L
 44.4%
H
8.0
19.5
|
L
 84.0%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharma Ltd |
|
3.6
|
0.5
|
L
 1.9%
H
0.5
0.6
|
L
 8%
H
0.5
0.6
|
L
 -8.5%
H
0.4
0.7
|
L
 -34.2%
H
0.4
0.9
|
L
 -59.7%
H
0.4
2.7
|
L
 -99.2%
H
0.2
93.6
|
L
 -99.9%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
1,513.0
|
25.1
|
L
 0.0%
H
24
27.0
|
L
 -1.6%
H
23.4
27.0
|
L
 -15.5%
H
16.5
30.8
|
L
 15.0%
H
16.5
34.0
|
L
 887.8%
H
2.0
38.3
|
L
 1020.1%
H
0.5
38.3
|
L
 315.4%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
1,251.9
|
19.4
|
L
 0.4%
H
18.4
20.1
|
L
 28.0%
H
14.3
20.6
|
L
 68.8%
H
9.9
20.6
|
L
 75.1%
H
8.7
20.6
|
L
 7.8%
H
8.7
28.8
|
L
 -84.0%
H
8.7
353
|
L
 -93.9%
H
8.7
416
|
L
 -96.9%
H
8.7
2605
|
| Genelux Corp |
|
115.2
|
2.6
|
L
 0.4%
H
2.5
2.6
|
L
 3.6%
H
2.3
2.6
|
L
 -4.1%
H
2.3
2.9
|
L
 -43.5%
H
2.3
5.0
|
L
 7.5%
H
2.0
8.5
|
L
 -90.7%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
3.6
|
1.5
|
L
 -2.5%
H
1.4
1.6
|
L
 -15.4%
H
1.4
1.9
|
L
 -25.6%
H
1.4
2.1
|
L
 -14.0%
H
1.4
3.6
|
L
 352.9%
H
0.1
13.0
|
L
 83.3%
H
0.1
13.0
|
L
 -63.5%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
86.8
|
0.4
|
L
 2.8%
H
0.3
0.4
|
L
 5.7%
H
0.3
0.4
|
L
 -36.2%
H
0.3
0.6
|
L
 -87.2%
H
0.3
3
|
L
 -53.8%
H
0.3
3.9
|
L
 -63.7%
H
0.3
3.9
|
L
 -96.0%
H
0.3
15.2
|
L
H
0.3
27.2
|
| GT Biopharma Inc |
|
14.2
|
0.5
|
L
 9.8%
H
0.4
0.5
|
L
 9.8%
H
0.4
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 -45.1%
H
0.4
0.9
|
L
 -80.9%
H
0.4
3.9
|
L
H
0.2
10.7
|
L
 -93.7%
H
0.2
19.7
|
L
 -100.0%
H
0.2
3315
|
| Genmab (ADR) |
|
16,882.5
|
27.5
|
L
 1.0%
H
26.6
27.5
|
L
 6.5%
H
25.8
27.5
|
L
 -2.4%
H
25.0
28.2
|
L
 -13.6%
H
25.0
35.4
|
L
 49.5%
H
17.2
35.4
|
L
 -26.7%
H
17.2
43
|
L
 -16.5%
H
17.2
49.1
|
L
 94.3%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
16.6
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
H
0.6
0.7
|
L
 -22.0%
H
0.6
0.9
|
L
 -49.7%
H
0.6
1.7
|
L
 -80.3%
H
0.6
10
|
L
 -88.5%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
5,607.9
|
8.2
|
L
 -0.1%
H
8
8.3
|
L
 10.0%
H
7.6
8.3
|
L
 -4.9%
H
7.4
8.9
|
L
 -10.8%
H
7.4
9.8
|
L
 23.9%
H
6.2
11.1
|
L
 14.9%
H
5.3
12.2
|
L
 -50.4%
H
5.3
19.1
|
L
 -46.8%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
9.1
|
0.6
|
L
 1.8%
H
0.5
0.6
|
L
 -30.9%
H
0.5
0.9
|
L
 -45.6%
H
0.5
1.3
|
L
 -47.7%
H
0.5
1.3
|
L
 -33.3%
H
0.5
2.1
|
L
 -73.1%
H
0.5
4.3
|
L
 -98.9%
H
0.5
55
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
49.1
|
1.0
|
L
 5.2%
H
0.9
1.0
|
L
 29.5%
H
0.8
1.0
|
L
 65.6%
H
0.6
1.0
|
L
 57.8%
H
0.5
1.0
|
L
 44.3%
H
0.5
2.4
|
L
 -59.9%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,604.5
|
27.7
|
L
 -0.8%
H
27.2
27.8
|
L
 4.5%
H
26.3
28.6
|
L
 -2.8%
H
26.3
29
|
L
 -25.8%
H
25.9
39.4
|
L
 -5.2%
H
25.5
40.9
|
L
 -10.9%
H
18.6
41.6
|
L
 -13.6%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,314.6
|
35.3
|
L
 -0.3%
H
34.3
36.5
|
L
 4.4%
H
33.1
36.5
|
L
 -10.0%
H
33.0
39.2
|
L
 -29.3%
H
33.0
54.9
|
L
 50.1%
H
20.9
54.9
|
L
 66.0%
H
7.6
59.2
|
L
 420.0%
H
5.4
59.2
|
L
 796.2%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,650.8
|
15.4
|
L
 1.9%
H
14.9
15.6
|
L
 11.7%
H
14.0
15.6
|
L
 13.1%
H
13.5
15.6
|
L
 13.0%
H
13.1
16.3
|
L
 7.2%
H
11.5
19.5
|
L
 16.5%
H
10.7
21.9
|
L
 -43.9%
H
7.4
43.9
|
L
 15.0%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,538.8
|
7.3
|
L
 2.2%
H
6.9
7.4
|
L
 -1.1%
H
6.6
7.9
|
L
 -18.9%
H
6.5
9.5
|
L
 261.4%
H
2.0
12.4
|
L
 158.0%
H
1.8
12.4
|
L
 334.5%
H
1.3
12.4
|
L
 -67.4%
H
1.2
22.6
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
2,875.0
|
32.7
|
L
 0.8%
H
31.9
33.5
|
L
 7.5%
H
30
34.5
|
L
 -5.6%
H
29.6
35.5
|
L
 -3.3%
H
29.5
39.3
|
L
 122.6%
H
13.5
39.3
|
L
 133.2%
H
13.3
47.7
|
L
 37.3%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
237.7
|
1.8
|
L
 -0.6%
H
1.7
1.8
|
L
 7.1%
H
1.6
1.8
|
L
 -7.7%
H
1.6
2.1
|
L
 -7.7%
H
1.5
2.3
|
L
 -2.2%
H
1.3
2.4
|
L
 -51.6%
H
0.8
4.4
|
L
 -95.2%
H
0.8
38.5
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
473.5
|
8.9
|
L
 3.7%
H
8.4
9.3
|
L
 9.7%
H
8.0
9.6
|
L
 4.4%
H
8
11.6
|
L
 64.6%
H
4.2
11.6
|
L
 496%
H
1.3
11.6
|
L
 413.8%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immuneering Corp (Class A) |
|
352.4
|
5.5
|
L
 2.3%
H
5.2
5.6
|
L
 9.9%
H
4.9
5.6
|
L
 5.4%
H
4.7
5.8
|
L
 -17.7%
H
4.0
8.5
|
L
 286.5%
H
1.1
10.1
|
L
 -34.1%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
151.3
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 6.4%
H
1.0
1.2
|
L
 -0.9%
H
1.0
1.5
|
L
 100%
H
0.6
1.5
|
L
 16%
H
0.5
1.5
|
L
 -20.5%
H
0.5
3.1
|
L
 -93.1%
H
0.5
17.0
|
L
 -99.7%
H
0.5
390
|
| Incyte |
|
19,091.5
|
95.9
|
L
 1.7%
H
92.6
96.1
|
L
 6.2%
H
90.1
96.1
|
L
 -3.0%
H
89.3
99.4
|
L
 -5.4%
H
89.3
112.3
|
L
 58.4%
H
53.6
112.3
|
L
 32.0%
H
50.3
112.3
|
L
 15.6%
H
50.3
112.3
|
L
 30.5%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
3.6
|
1.6
|
L
 -5.9%
H
1.6
1.7
|
L
 -10.1%
H
1.6
1.9
|
L
 -20.4%
H
1.6
2.0
|
L
 -41.6%
H
1.5
3.7
|
L
 247.8%
H
0.3
13.4
|
L
 -11.6%
H
0.3
13.4
|
L
 -91.2%
H
0.3
28.8
|
L
 -99.5%
H
0.3
8800
|
| Indivior PLC |
|
3,715.0
|
30.5
|
L
 -0.6%
H
29.7
30.6
|
L
 5.2%
H
28.7
31.3
|
L
 -5.3%
H
27.7
35.3
|
L
 -14.7%
H
27.7
37.7
|
L
 233.0%
H
8.6
38
|
L
 77.0%
H
7.3
38
|
L
 1556.0%
H
1.8
38
|
L
 1248.2%
H
0.4
38
|
| InMed Pharma Inc |
|
2.0
|
0.7
|
L
 1.5%
H
0.6
0.7
|
L
 3.0%
H
0.6
0.7
|
L
 -26.9%
H
0.6
1.0
|
L
 -39.3%
H
0.6
1.4
|
L
 -63.4%
H
0.6
8.0
|
L
 -96.9%
H
0.6
41.6
|
L
 -100.0%
H
0.6
1995
|
L
 -100.0%
H
0.6
32175
|
| Inovio Pharma Inc |
|
78.1
|
1.1
|
L
 -35.1%
H
1.1
1.4
|
L
 -29.8%
H
1.1
1.8
|
L
 -34.7%
H
1.1
1.8
|
L
 -33.1%
H
1.1
2.0
|
L
 -27.6%
H
1.1
3.0
|
L
 56.9%
H
0.3
14.8
|
L
 -88.1%
H
0.3
14.8
|
L
 -88.3%
H
0.3
33.8
|
| Insmed Inc |
|
35,012.1
|
162.4
|
L
 -1.5%
H
157.5
164.5
|
L
 11.8%
H
149.4
166
|
L
 8.4%
H
135.7
166
|
L
 -8.3%
H
135.7
186.2
|
L
 134.8%
H
60.4
212.8
|
L
 870.9%
H
16.3
212.8
|
L
 358.3%
H
16.0
212.8
|
L
 1165.0%
H
9.0
212.8
|
| Innoviva Inc |
|
1,702.4
|
23.0
|
L
 -1.8%
H
22.9
23.4
|
L
 1.5%
H
22.5
23.6
|
L
 1.1%
H
21.6
23.6
|
L
 15.7%
H
19
25.1
|
L
 29.7%
H
16.5
25.1
|
L
 101.7%
H
11.2
25.1
|
L
 92.2%
H
10.6
25.1
|
L
 74.0%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
12,354.7
|
74.8
|
L
 -0.5%
H
73.4
75.1
|
L
 3.7%
H
71.5
76.5
|
L
 -5.9%
H
68.9
79.0
|
L
 -6.1%
H
68.9
86.7
|
L
 176.1%
H
24.0
86.7
|
L
 111.6%
H
24.0
86.7
|
L
 66.0%
H
24.0
86.7
|
L
 77.0%
H
19.6
86.7
|
| Ironwood Pharma Inc (Class A) |
|
577.2
|
3.5
|
L
 -9.2%
H
3.5
3.8
|
L
 15.7%
H
3.1
3.9
|
L
 -5.4%
H
3.0
3.9
|
L
 -17.1%
H
3.0
5.6
|
L
 164.2%
H
0.5
5.8
|
L
 -66.5%
H
0.5
15.7
|
L
 -67.5%
H
0.5
15.7
|
L
 -62.3%
H
0.5
17.7
|
| I-Mab (ADR) |
|
280.1
|
2.4
|
L
 -1.2%
H
2.4
2.6
|
L
 -4.3%
H
2.1
2.7
|
L
 -21.9%
H
2.1
3.9
|
L
 -43.1%
H
2.1
5.2
|
L
 257.4%
H
0.6
6.8
|
L
 -33.1%
H
0.6
6.8
|
L
 -95.1%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
6.5
|
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
H
0.7
0.9
|
L
 6.7%
H
0.7
0.9
|
L
H
0.7
1.3
|
L
 -55.1%
H
0.7
2.4
|
L
 -60%
H
0.7
6.0
|
L
 -86.8%
H
0.7
6.2
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
128.4
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 5.4%
H
1.3
1.4
|
L
 -15.4%
H
1.2
1.7
|
L
 -24.7%
H
1.2
1.9
|
L
 -25.1%
H
1.2
2.6
|
L
 -57.8%
H
1.2
3.6
|
L
 -68.2%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Jaguar Health Inc |
|
5.0
|
0.4
|
L
 -2.4%
H
0.4
0.4
|
L
 17.7%
H
0.3
0.5
|
L
 -39.4%
H
0.3
0.7
|
L
 -60%
H
0.3
1.9
|
L
 -90.9%
H
0.3
15.5
|
L
 -98.9%
H
0.3
73.2
|
L
 -100.0%
H
0.3
30780
|
L
 -100.0%
H
0.3
999999
|
| Jazz Pharma PLC |
|
11,508.7
|
187.0
|
L
 -0.7%
H
185
188.4
|
L
 2.3%
H
182.0
192
|
L
 -0.9%
H
176.7
192
|
L
 8.0%
H
157.0
198
|
L
 69.9%
H
95.5
198
|
L
 29.8%
H
95.5
198
|
L
 13.2%
H
95.5
198
|
L
 37.9%
H
86.9
198
|
| Kala Pharma Inc |
|
154.9
|
0.2
|
L
 6.3%
H
0.2
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 -50%
H
0.2
0.5
|
L
 -72.6%
H
0.2
0.7
|
L
 -96.0%
H
0.2
20.6
|
L
 -98.8%
H
0.2
20.6
|
L
 -100.0%
H
0.2
419.2
|
L
H
0.2
1337.5
|
| KalVista Pharma Inc |
|
1,019.3
|
19.9
|
L
 0.7%
H
19.3
20.1
|
L
 3.0%
H
18.2
21.3
|
L
 21.6%
H
15.1
21.3
|
L
 28.7%
H
14.2
21.3
|
L
 85.8%
H
9.2
21.3
|
L
 148.1%
H
7.2
21.3
|
L
 -27.5%
H
4.1
30.7
|
L
 122.1%
H
4.1
45
|
| Kiniksa Pharma Ltd (Class A) |
|
3,736.5
|
48.8
|
L
 1.4%
H
46.8
48.9
|
L
 6.7%
H
44.8
49.3
|
L
 3.3%
H
44.4
49.3
|
L
 16.2%
H
37.0
49.3
|
L
 139.8%
H
18.3
49.3
|
L
 362.7%
H
10.3
49.3
|
L
 164.2%
H
7.4
49.3
|
L
H
5.0
49.3
|
| Kiora Pharma Inc |
|
7.7
|
1.9
|
L
 -0.5%
H
1.8
2.0
|
L
 3.2%
H
1.8
2.0
|
L
 -4.9%
H
1.8
2.2
|
L
 -4.0%
H
1.8
2.5
|
L
 -26.2%
H
1.8
4.2
|
L
 -41.7%
H
0.4
5.6
|
L
 -99.1%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2400
|
| Karyopharm Therapeutics Inc |
|
132.8
|
5.9
|
L
 1.2%
H
5.5
6.1
|
L
 7.5%
H
5.3
6.1
|
L
 -35.6%
H
5
9.2
|
L
 -18.1%
H
5
11.0
|
L
 52.6%
H
3.6
11.0
|
L
 -90.0%
H
0.6
73.1
|
L
 -96.4%
H
0.6
221.0
|
L
 -95.8%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
236.6
|
12
|
L
 2.7%
H
11.3
12.0
|
L
 13.1%
H
10.4
12.0
|
L
 -12.9%
H
10.4
13.1
|
L
 -35.3%
H
10.4
19.9
|
L
 20.2%
H
9.1
22.6
|
L
 -71.4%
H
9.1
73
|
L
 -79.6%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
17.8
|
0.8
|
L
 4.1%
H
0.7
0.8
|
L
 4.1%
H
0.5
0.8
|
L
 -6.1%
H
0.5
0.9
|
L
 -35.3%
H
0.5
1.2
|
L
 -39.4%
H
0.3
3.8
|
L
 92.5%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics Ltd (ADR) |
|
83.9
|
7.3
|
L
 2.2%
H
7.0
7.5
|
L
 2.5%
H
7.0
7.8
|
L
 -16.4%
H
6.8
9.1
|
L
 46.8%
H
4.9
10.5
|
L
 106.2%
H
2.9
17.4
|
L
 -86.7%
H
2.9
84
|
L
 -98.8%
H
2.9
744.5
|
L
 -98.4%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
25.9
|
1.0
|
L
 19.5%
H
0.9
1.1
|
L
 40.5%
H
0.7
1.1
|
L
 46.5%
H
0.7
1.1
|
L
 60%
H
0.6
1.1
|
L
 -26.2%
H
0.5
1.7
|
L
 -56.5%
H
0.5
6.9
|
L
 -81.4%
H
0.5
12.5
|
L
 -69.3%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
143.9
|
3.8
|
L
H
3.7
3.9
|
L
 4.9%
H
3.6
3.9
|
L
 -45.6%
H
3.6
7.2
|
L
 -50.4%
H
3.6
9.0
|
L
 -27.4%
H
3.6
9.0
|
L
 9.7%
H
3.5
11.5
|
L
 -63.9%
H
1.5
12.9
|
L
 -63.1%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
3,980.1
|
199.6
|
L
 0.0%
H
194.7
201.4
|
L
 2.1%
H
188.7
205.5
|
L
 -4.5%
H
188.7
227.9
|
L
 5.0%
H
175.9
227.9
|
L
 100.5%
H
93.6
227.9
|
L
 180.7%
H
49.3
227.9
|
L
 100.1%
H
46.8
227.9
|
L
 177.1%
H
36.9
227.9
|
| Atyr Pharma Inc |
|
83.3
|
0.9
|
L
H
0.8
0.9
|
L
 13.3%
H
0.7
0.9
|
L
 -11.5%
H
0.7
1.0
|
L
 11.8%
H
0.7
1.1
|
L
 -67.6%
H
0.6
7.3
|
L
 -59.5%
H
0.6
7.3
|
L
 -81.4%
H
0.6
13.1
|
L
 -98.3%
H
0.6
90.9
|
| Lipocine Inc |
|
15.0
|
2.1
|
L
 -77.8%
H
1.8
2.1
|
L
 -71.3%
H
1.8
9.3
|
L
 -75.7%
H
1.8
9.3
|
L
 -74.4%
H
1.8
12.4
|
L
 -31.9%
H
1.8
12.4
|
L
 -61.8%
H
1.8
12.4
|
L
 -92.2%
H
1.8
32.1
|
L
 -98.9%
H
1.8
215.2
|
| Liquidia Corp |
|
3,320.2
|
37.7
|
L
 0.6%
H
36.5
37.8
|
L
 7.6%
H
34.8
38.6
|
L
 9.6%
H
31.8
39.6
|
L
 20%
H
29.1
46.7
|
L
 192.1%
H
11.3
46.7
|
L
 443.7%
H
5.7
46.7
|
L
 1265.2%
H
2.3
46.7
|
L
H
2.3
46.7
|
| Lisata Therapeutics Inc |
|
45.3
|
5.0
|
L
 0.2%
H
5.0
5.0
|
L
H
5
5.0
|
L
 16.5%
H
4.1
5.1
|
L
 156.1%
H
1.9
5.1
|
L
 152.3%
H
1.8
5.1
|
L
 57.9%
H
1.8
5.1
|
L
 -82.4%
H
1.8
28.8
|
L
 -95.6%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
18.2
|
1.6
|
L
 14.1%
H
1.4
1.8
|
L
 44.6%
H
1.2
2.1
|
L
 -42.6%
H
1.1
2.8
|
L
 -47.9%
H
1.1
3.6
|
L
 -45.8%
H
1.1
5.7
|
L
 -67.4%
H
1.1
12.0
|
L
 -91.9%
H
1.1
20.9
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
673.7
|
1.6
|
L
 -3.1%
H
1.6
1.6
|
L
 -3.6%
H
1.5
1.7
|
L
 -2.5%
H
1.5
1.8
|
L
 39.5%
H
1.1
1.8
|
L
 278.6%
H
0.4
1.8
|
L
 -32.1%
H
0.3
3.8
|
L
 -72.9%
H
0.3
6.3
|
L
 -87.6%
H
0.3
19.6
|
| Legend Biotech Corp (ADR) |
|
3,540.1
|
19.1
|
L
 0.5%
H
18.7
19.4
|
L
 13.9%
H
16.7
19.4
|
L
 7.2%
H
16.7
20.5
|
L
 -11.0%
H
16.2
24.1
|
L
 -40.2%
H
16.2
45.3
|
L
 -58.6%
H
16.2
77.3
|
L
 -33.0%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
5.9
|
0.8
|
L
 2.6%
H
0.7
0.8
|
L
 8.3%
H
0.7
0.8
|
L
 -18.8%
H
0.7
1.0
|
L
 -27.1%
H
0.5
1.2
|
L
 -36.1%
H
0.5
7
|
L
 -99.7%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
12.4
|
2.3
|
L
 4.0%
H
2.2
2.3
|
L
 -4.9%
H
2.2
2.4
|
L
 -0.9%
H
1.8
2.5
|
L
 -35.9%
H
1.8
5.3
|
L
 -88.7%
H
1.8
28.6
|
L
 -99.3%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Madrigal Pharma Inc |
|
12,545.6
|
546.9
|
L
 3.2%
H
522.5
548.0
|
L
 7.1%
H
502.1
548.0
|
L
 25.8%
H
418.7
572.2
|
L
 -7.9%
H
416.2
593.0
|
L
 74.0%
H
265
615
|
L
 127.3%
H
119.8
615
|
L
 361.2%
H
52.3
615
|
L
 6334%
H
6.6
615
|
| MediWound Ltd |
|
216.0
|
16.8
|
L
 3.8%
H
15.5
17.5
|
L
 11.7%
H
14.9
17.5
|
L
 -4.5%
H
14.9
17.6
|
L
 -8.7%
H
14.9
19.7
|
L
 12.3%
H
14.1
22.5
|
L
 26.6%
H
7.1
24
|
L
 -54.3%
H
7.1
43.5
|
L
 -70.0%
H
7.1
62.3
|
| MEI Pharma Inc |
|
40.7
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 1.8%
H
1.0
1.2
|
L
 -8.2%
H
1.0
1.3
|
L
 -27.3%
H
1.0
1.7
|
L
 -44%
H
1.0
9
|
L
 -75.7%
H
1.0
9
|
L
 -98.3%
H
1.0
78.2
|
L
 -95.6%
H
1.0
102.8
|
| Macrogenics Inc |
|
195.1
|
3.1
|
L
 5.9%
H
2.8
3.2
|
L
 4.8%
H
2.7
3.2
|
L
 47.6%
H
2.0
3.5
|
L
 90.7%
H
1.6
3.5
|
L
 189.6%
H
1.0
3.5
|
L
 -58.7%
H
1.0
21.9
|
L
 -90.5%
H
1.0
36.5
|
L
 -84.5%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
5.5
|
0.3
|
L
 -5.6%
H
0.3
0.4
|
L
 -30.6%
H
0.3
0.5
|
L
 -10.5%
H
0.2
0.5
|
L
 -60%
H
0.2
1.0
|
L
 -81.5%
H
0.2
2.9
|
L
 -76.9%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
86
|
L
 1.7%
H
81.8
87.5
|
L
 6%
H
77.6
88.5
|
L
 38.6%
H
59.4
88.5
|
L
 116.7%
H
35.8
88.5
|
L
 336.8%
H
16.6
88.5
|
L
 607.2%
H
9.1
88.5
|
L
 -58.1%
H
5.1
227.2
|
L
H
5.1
336
|
| Mirum Pharma Inc |
|
5,682.4
|
94.2
|
L
 -0.5%
H
92.4
95.1
|
L
 6.5%
H
87.0
97.5
|
L
 1.2%
H
84.3
97.5
|
L
 20.6%
H
73.8
109.3
|
L
 124.1%
H
36.9
109.3
|
L
 277.4%
H
22.3
109.3
|
L
 357.1%
H
12.8
109.3
|
L
H
6.5
109.3
|
| Milestone Pharma Inc |
|
162.4
|
1.4
|
L
 5.3%
H
1.2
1.4
|
L
 32.7%
H
1
1.4
|
L
 -16.4%
H
1
1.8
|
L
 -32.7%
H
1
2.3
|
L
 97.1%
H
0.6
3.1
|
L
 -66.1%
H
0.6
4.5
|
L
 -77.2%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,245.2
|
17.4
|
L
 5.1%
H
16.0
17.5
|
L
 0.2%
H
15.8
19
|
L
 -4.3%
H
15.8
19.3
|
L
 45.3%
H
11.1
19.5
|
L
 -53.4%
H
6.0
62.8
|
L
 -8.7%
H
6.0
65.0
|
L
 69.2%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
770.3
|
2.5
|
L
 -1.6%
H
2.4
2.5
|
L
 9.7%
H
2.3
2.6
|
L
 -15.3%
H
2.2
3.0
|
L
 -55.4%
H
2.2
6.5
|
L
 -47.3%
H
2.2
6.5
|
L
 -38.1%
H
2.2
7.6
|
L
 -39.9%
H
2.2
7.6
|
L
 -70.4%
H
0.7
10.2
|
| Mind Medicine Inc |
|
2,061.8
|
20.7
|
L
 0.4%
H
20.0
21.1
|
L
 15.7%
H
17.1
21.1
|
L
 16.4%
H
16.9
21.1
|
L
 51.6%
H
12.9
21.1
|
L
 280.9%
H
4.7
21.1
|
L
 591.6%
H
2.4
21.1
|
L
 -51.8%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
70.9
|
1.4
|
L
 1.4%
H
1.4
1.5
|
L
 4.4%
H
1.4
1.5
|
L
H
1.3
1.6
|
L
 8.3%
H
1.3
1.9
|
L
 16.1%
H
1.1
2.0
|
L
 -31.4%
H
1.1
2.7
|
L
 -72.0%
H
1.1
5.2
|
L
 -84%
H
1.1
14.5
|
| TNF Pharma Inc |
|
27.2
|
3.5
|
L
 1.8%
H
3.3
3.5
|
L
 0.6%
H
3.1
3.6
|
L
 -6.5%
H
3.1
5.0
|
L
 -18.2%
H
3.1
6.3
|
L
 -90.7%
H
2.5
37
|
L
 -99.9%
H
2.5
7050
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,793.0
|
33.0
|
L
 0.6%
H
31.6
33.2
|
L
 10.0%
H
29.1
33.4
|
L
 5.8%
H
28.5
33.4
|
L
 -6.3%
H
28.5
37.8
|
L
 108.7%
H
14.1
42
|
L
 144.0%
H
5.6
42
|
L
 234.6%
H
5.6
42
|
L
H
5.6
42
|
| Neurocrine Biosciences Inc |
|
13,207.8
|
131.6
|
L
 -0.7%
H
130
133.8
|
L
 2.6%
H
128.2
134.0
|
L
 -1.4%
H
125.1
134.0
|
L
 -6.4%
H
122.1
142.8
|
L
 37.6%
H
84.2
160.2
|
L
 31.1%
H
84.2
160.2
|
L
 34.0%
H
71.9
160.2
|
L
 206.5%
H
37.3
160.2
|
| Minerva Neurosciences Inc |
|
228.5
|
5.3
|
L
 -5.7%
H
5.3
5.7
|
L
 -14.6%
H
5.3
6.4
|
L
 -22.7%
H
5.0
8.8
|
L
 34.7%
H
3.8
8.8
|
L
 285.4%
H
1.2
12.5
|
L
 225.9%
H
1.2
13.5
|
L
 -77.8%
H
1.2
28.3
|
L
 -89.3%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,208.7
|
77.0
|
L
 1.7%
H
73.0
78
|
L
 12.1%
H
64.1
78.8
|
L
 8.3%
H
62.5
78.8
|
L
 77.3%
H
33.4
78.8
|
L
 829.8%
H
6.5
78.8
|
L
 643.9%
H
6.2
78.8
|
L
 -74.8%
H
6.2
313.5
|
L
 -64.0%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
10.3
|
2.3
|
L
 -3.8%
H
2.2
2.4
|
L
 1.8%
H
1.8
2.5
|
L
 -20.1%
H
1.8
3.1
|
L
 8.1%
H
1.8
3.3
|
L
 -84.8%
H
1.8
30.8
|
L
 -99.6%
H
1.2
640
|
L
 -99.9%
H
1.2
1668
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,603.8
|
15.5
|
L
 0.2%
H
15
15.7
|
L
 5.1%
H
14.4
16.2
|
L
 -4.6%
H
14.0
16.2
|
L
 -14.1%
H
14.0
20.2
|
L
 60.1%
H
8.2
22.5
|
L
 78.3%
H
4.2
29.6
|
L
 -50.0%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
27.7
|
0.8
|
L
 9.2%
H
0.8
0.8
|
L
 13.7%
H
0.7
0.8
|
L
 -6.7%
H
0.6
1.1
|
L
 6.4%
H
0.6
1.1
|
L
 -16.2%
H
0.6
2.6
|
L
 -51.5%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
72.7
|
2.2
|
L
 1.9%
H
2.1
2.2
|
L
 0.5%
H
2.1
2.2
|
L
 17.7%
H
1.6
2.5
|
L
 -16.0%
H
1.6
2.6
|
L
 22.9%
H
1.6
3.8
|
L
 -62.0%
H
1.1
54
|
L
 -99.4%
H
1.1
488
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
200.3
|
7.6
|
L
 -0.5%
H
7.4
7.6
|
L
 1.1%
H
7.2
7.9
|
L
 -16.3%
H
7.2
9.9
|
L
 -11.2%
H
7.2
9.9
|
L
 -8.4%
H
5.6
11.5
|
L
 -43.5%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
38.2
|
10.7
|
L
 1.8%
H
10.3
10.7
|
L
 7.1%
H
8.6
11.3
|
L
 -14.9%
H
8.6
14.4
|
L
 -19.3%
H
8.6
14.7
|
L
 129.1%
H
2.8
15.7
|
L
 -39.6%
H
2.8
30.8
|
L
 -91.1%
H
2.8
125.8
|
L
H
2.8
1308
|
| Ocugen Inc |
|
586.9
|
1.8
|
L
H
1.7
1.8
|
L
 -4.3%
H
1.7
1.9
|
L
 -8.7%
H
1.5
2.7
|
L
 29.7%
H
1.3
2.7
|
L
 171.2%
H
0.6
2.7
|
L
 118.3%
H
0.3
2.7
|
L
 -73.3%
H
0.3
17.7
|
L
 -98.8%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,544.1
|
26.6
|
L
 -1.5%
H
26.1
27
|
L
 7.9%
H
24.3
27.9
|
L
 -3.9%
H
24.0
29.2
|
L
 33.2%
H
19.7
30.7
|
L
 71.8%
H
14
30.7
|
L
 228.8%
H
7.8
30.7
|
L
H
6.3
30.7
|
L
H
6.3
30.7
|
| Ocular Therapeutix Inc |
|
1,848.2
|
8.5
|
L
 1.9%
H
8.1
8.7
|
L
 12.5%
H
7.4
8.8
|
L
 -23.1%
H
7.4
11.1
|
L
 -28.2%
H
6.2
13.0
|
L
 33.5%
H
5.8
16.4
|
L
 69.5%
H
2
16.4
|
L
 -51.2%
H
2
19.8
|
L
 -19.3%
H
2
24.3
|
| Opus Genetics Inc |
|
323.7
|
4.6
|
L
 -3.0%
H
4.5
4.8
|
L
 4.6%
H
4.2
5.0
|
L
 -0.4%
H
4.2
5.3
|
L
 114.6%
H
1.9
5.3
|
L
 411.2%
H
0.7
5.3
|
L
 -12.3%
H
0.7
6.6
|
L
 -28.7%
H
0.7
7.3
|
L
 -97.2%
H
0.7
340.8
|
| Olema Pharma Inc |
|
1,312.6
|
15.1
|
L
 -0.4%
H
14.6
15.1
|
L
 10.2%
H
13.2
16.0
|
L
 -38.1%
H
13.0
24.4
|
L
 -40.4%
H
13.0
29.5
|
L
 363.4%
H
2.9
36.3
|
L
 364.8%
H
2.9
36.3
|
L
 -56.2%
H
2
36.7
|
L
H
2
60.3
|
| Omeros Corp |
|
784.8
|
10.9
|
L
 -9.8%
H
10.8
11.8
|
L
 10.3%
H
9.8
13
|
L
 -6.0%
H
9.8
13
|
L
 -33.5%
H
9.8
16.4
|
L
 54.4%
H
3.0
17.7
|
L
 138.0%
H
0.9
17.7
|
L
 -40.1%
H
0.9
19.4
|
L
 -31.0%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
995.7
|
8.9
|
L
 18.9%
H
7.2
9.0
|
L
 -26.3%
H
7.2
13.0
|
L
 -34.2%
H
7.2
14.0
|
L
 8.8%
H
7.2
14.3
|
L
 82.2%
H
3.9
14.9
|
L
 60.8%
H
3.9
16.7
|
L
 -61.7%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
138.3
|
3.4
|
L
 0.9%
H
3.3
3.4
|
L
 3.3%
H
3.2
3.5
|
L
 -5.5%
H
3.2
3.7
|
L
 17.5%
H
2.9
3.8
|
L
 62.9%
H
1.8
3.8
|
L
 58.3%
H
1.7
5.3
|
L
 -66.5%
H
1.7
31.5
|
L
 -55.2%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
23.0
|
0.2
|
L
 4.8%
H
0.2
0.2
|
L
 4.8%
H
0.2
0.2
|
L
 -50%
H
0.2
0.5
|
L
 -66.7%
H
0.2
0.7
|
L
 -81.7%
H
0.2
3.0
|
L
 -99.9%
H
0.2
812
|
L
 -100.0%
H
0.2
1308
|
L
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
332.3
|
2.2
|
L
 1.9%
H
2.1
2.2
|
L
 -4.4%
H
2.0
2.3
|
L
 31.0%
H
1.7
2.7
|
L
 25%
H
1.4
2.7
|
L
 685.7%
H
0.2
2.7
|
L
 -13.4%
H
0.2
4.1
|
L
 -45.9%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
2,250.5
|
55.5
|
L
 1.4%
H
51.7
55.6
|
L
 3.0%
H
51.7
57.6
|
L
 7%
H
45.2
57.6
|
L
 48.9%
H
36.8
57.6
|
L
 189.3%
H
16.2
57.6
|
L
 275.9%
H
9.4
57.6
|
L
 122.1%
H
9.4
57.6
|
L
 103.4%
H
9.4
57.6
|
| Palisade Bio Inc |
|
316.8
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 -5.5%
H
1.5
2.0
|
L
 8.6%
H
1.5
2.2
|
L
 -24.4%
H
1.5
2.6
|
L
 162.5%
H
0.5
2.6
|
L
 -93.8%
H
0.4
36.6
|
L
 -100.0%
H
0.4
8505
|
L
 -100.0%
H
0.4
924300
|
| Puma biotech Inc |
|
351.0
|
6.9
|
L
 2.1%
H
6.5
7.0
|
L
 13.5%
H
6.1
7.0
|
L
 7.8%
H
5.8
7.0
|
L
 19.6%
H
5.5
7.7
|
L
 137.9%
H
2.6
7.7
|
L
 144.7%
H
2.1
7.7
|
L
 -30.7%
H
1.6
12.0
|
L
 -75.8%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
919.1
|
22.7
|
L
 -0.4%
H
22.2
22.9
|
L
 -0.8%
H
22.2
23.6
|
L
 -0.7%
H
21.2
24.1
|
L
 -7.2%
H
18.8
26.5
|
L
 -1.7%
H
18.8
27.6
|
L
 -45.1%
H
11.2
48.6
|
L
 -67.6%
H
11.2
82.2
|
L
 -59.1%
H
11.2
82.2
|
| Processa Pharma Inc |
|
7.4
|
2.8
|
L
 6.5%
H
2.6
3.2
|
L
 14.0%
H
2.3
3.2
|
L
 -1.1%
H
2.1
3.3
|
L
 -5.5%
H
1.8
3.8
|
L
 -67.4%
H
1.8
19.6
|
L
 -98.9%
H
1.8
450
|
L
 -99.9%
H
1.8
5750
|
L
 -99.9%
H
1.8
17937.5
|
| PDS biotech Corp |
|
35.7
|
0.6
|
L
 4.9%
H
0.6
0.6
|
L
 18.5%
H
0.5
0.6
|
L
 -8.6%
H
0.5
0.7
|
L
 -22.9%
H
0.5
1.2
|
L
 -32.6%
H
0.5
1.9
|
L
 -88.9%
H
0.5
10.3
|
L
 -86.4%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| Phathom Pharma Inc |
|
893.6
|
11.3
|
L
 1.8%
H
10.8
11.4
|
L
 7.2%
H
10.2
11.8
|
L
 2.5%
H
10
11.9
|
L
 -27.8%
H
10
18.1
|
L
 132.4%
H
2.2
18.3
|
L
 41.0%
H
2.2
19.7
|
L
 -69.3%
H
2.2
42
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
1,855.2
|
28.6
|
L
 -3.0%
H
27.8
28.8
|
L
 4.4%
H
26.5
29.9
|
L
 6.6%
H
25.0
29.9
|
L
 7.9%
H
23.6
29.9
|
L
 100%
H
11.5
29.9
|
L
 236.4%
H
7.9
33
|
L
 2.2%
H
1.8
33
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
8,644.3
|
310.4
|
L
 -2.8%
H
308.5
321.9
|
L
 7.0%
H
271.9
338.3
|
L
 -4.5%
H
271.9
338.3
|
L
 8.4%
H
266.9
356
|
L
 850.6%
H
26.7
356
|
L
 2391.0%
H
11.9
356
|
L
 -32.9%
H
11.9
512.7
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
1.8
|
2.1
|
L
 -0.5%
H
2.0
2.1
|
L
 1.0%
H
1.8
2.3
|
L
 -24.7%
H
1.8
3.0
|
L
 200%
H
0.6
3.7
|
L
 0.5%
H
0.6
3.7
|
L
 -93.8%
H
0.2
158.5
|
L
 -99.3%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
180.2
|
1.7
|
L
H
1.6
1.7
|
L
 24.8%
H
1.5
1.8
|
L
 0.6%
H
1.4
2.0
|
L
 -14.1%
H
1.3
2.3
|
L
 44.9%
H
1.1
3.1
|
L
 -21.9%
H
1.1
4.6
|
L
 -73.9%
H
0.5
9.1
|
L
 -66.5%
H
0.5
24
|
| Plus Therapeutics Inc |
|
24.4
|
3.6
|
L
 -8.7%
H
3.3
3.8
|
L
 -38.1%
H
3.2
5.7
|
L
 -53.9%
H
3.2
8.2
|
L
 -74.4%
H
3.2
15.3
|
L
 -82.0%
H
3.2
30.5
|
L
 -96.5%
H
3.2
127.5
|
L
 -99.6%
H
3.2
1327.5
|
L
 -100.0%
H
3.2
1012500
|
| PTC Therapeutics Inc |
|
5,609.6
|
67.8
|
L
 -1.4%
H
67.0
68.7
|
L
 2.5%
H
64.4
70.4
|
L
 5.4%
H
61.4
71
|
L
 -11.7%
H
61.4
80.2
|
L
 56.7%
H
36.0
87.5
|
L
 42.7%
H
17.5
87.5
|
L
 37.8%
H
17.5
87.5
|
L
 898.1%
H
4.0
87.5
|
| Pulmatrix Inc |
|
4.8
|
1.3
|
L
 -0.8%
H
1.3
1.4
|
L
 -3.7%
H
1.2
1.5
|
L
 -39.4%
H
1.2
2.5
|
L
 -42.0%
H
1.2
3.4
|
L
 -75.7%
H
1.2
9.4
|
L
 -55.1%
H
1.2
10.4
|
L
 -95.4%
H
1.2
28.6
|
L
 -99.8%
H
1.2
1396
|
| Polypid Ltd |
|
83.8
|
4.4
|
L
H
4.3
4.4
|
L
 2.6%
H
4.2
4.5
|
L
 3.3%
H
4.0
4.7
|
L
 0.9%
H
4.0
5.1
|
L
 74.9%
H
2.3
5.1
|
L
 -66.7%
H
2.3
14.1
|
L
 -98.5%
H
2.3
303
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
93.0
|
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 13.0%
H
1.3
1.6
|
L
 -0.7%
H
1.3
1.7
|
L
 28.7%
H
1.1
2.2
|
L
 62.6%
H
0.8
5.6
|
L
 -56.9%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,157.9
|
16.6
|
L
 -1.8%
H
15.7
16.9
|
L
 1.9%
H
15.7
17.1
|
L
 2.5%
H
14.5
17.3
|
L
 -3.0%
H
14.5
21.3
|
L
 116.1%
H
7.5
21.3
|
L
 35.9%
H
6.7
21.3
|
L
 27.0%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
3.8
|
4.1
|
L
 -4.2%
H
4.0
4.2
|
L
 2.8%
H
3.6
4.3
|
L
 -18.1%
H
3.6
5.2
|
L
 -37.7%
H
3.6
7.3
|
L
 -84.0%
H
3.6
29.4
|
L
 -99.9%
H
3.6
8640
|
L
 -100.0%
H
3.6
27000
|
L
 -100.0%
H
3.6
278000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
68.2
|
0.3
|
L
 13.3%
H
0.3
0.3
|
L
 -27.7%
H
0.3
0.5
|
L
 -69.1%
H
0.3
1.1
|
L
 -90.5%
H
0.3
4.3
|
L
 -96.8%
H
0.3
17.2
|
L
 -94.8%
H
0.3
17.2
|
L
 -98.5%
H
0.3
27.8
|
L
H
0.3
110
|
| Quoin Pharma Ltd (ADR) |
|
12.7
|
7.0
|
L
 15.8%
H
5.9
7.1
|
L
 9.5%
H
5.9
7.1
|
L
 -17.4%
H
5.9
10.8
|
L
 -50.1%
H
5.9
14.5
|
L
 -95.7%
H
5.1
167.3
|
L
 -99.8%
H
5.1
8400
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
2,207.2
|
22.5
|
L
 4.8%
H
20.8
22.5
|
L
 15.8%
H
19.1
22.5
|
L
 3.0%
H
18.3
23.2
|
L
 -4.9%
H
18.3
25.8
|
L
 -30.8%
H
18.3
42.4
|
L
 -44.1%
H
18.3
60.4
|
L
 -80.2%
H
18.3
120
|
L
 -66.8%
H
18.3
179.7
|
| Regeneron Pharma |
|
80,542.6
|
761.9
|
L
 -2.0%
H
745
770.1
|
L
 3.3%
H
741.5
781.2
|
L
 -3.3%
H
727.9
788.7
|
L
 -1.9%
H
718.4
821.1
|
L
 32.9%
H
476.5
821.1
|
L
 -7.3%
H
476.5
1211.2
|
L
 60.4%
H
469.8
1211.2
|
L
 88.0%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
15,230.3
|
30.8
|
L
 -8.7%
H
29.5
38.0
|
L
 20.0%
H
23.0
40
|
L
 21.0%
H
20
40
|
L
 50.0%
H
20
69
|
L
 3523.5%
H
0.7
83.6
|
L
 3798.7%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
6,634.7
|
117.8
|
L
 -0.5%
H
114.2
121.7
|
L
 7.0%
H
110.5
121.7
|
L
 -6.4%
H
109.7
129
|
L
 -28.3%
H
109.7
175.8
|
L
 5.2%
H
103.0
175.8
|
L
 -27.7%
H
103.0
211.1
|
L
 -39.7%
H
103.0
327.3
|
L
 338.0%
H
21.1
327.3
|
| Regenxbio Inc |
|
440.3
|
8.5
|
L
 -1.2%
H
8.1
8.7
|
L
 9.9%
H
7.6
8.9
|
L
 -6.7%
H
7.6
10.8
|
L
 -37.1%
H
7.6
16.2
|
L
 35.6%
H
5.0
16.2
|
L
 -55.4%
H
5.0
28.8
|
L
 -75.2%
H
5.0
46.5
|
L
 -20.8%
H
5.0
85.1
|
| Rigel Pharma |
|
508.6
|
27.5
|
L
 0.1%
H
26.8
27.6
|
L
 6.7%
H
25.7
28.2
|
L
 -7.1%
H
25.0
30.1
|
L
 -34.2%
H
25.0
49.1
|
L
 59.7%
H
15.5
52.2
|
L
 2156.6%
H
0.7
52.2
|
L
 702.6%
H
0.6
52.2
|
L
 1071.5%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
733.2
|
7.0
|
L
 -1.6%
H
6.6
7.1
|
L
 8.7%
H
6.3
7.4
|
L
 46.5%
H
4.2
7.5
|
L
 60.0%
H
3.2
7.5
|
L
 2488.9%
H
0.2
7.5
|
L
 190.0%
H
0.2
7.5
|
L
 -80.9%
H
0.2
40
|
L
 -5.5%
H
0.2
54
|
| RenovoRx Inc |
|
44.2
|
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 -13.3%
H
1.0
1.1
|
L
 15.3%
H
0.8
1.3
|
L
 16.7%
H
0.8
1.3
|
L
 11.4%
H
0.7
1.5
|
L
 -67.7%
H
0.6
3.3
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
20,275.8
|
28.3
|
L
 1.8%
H
26.6
28.6
|
L
 6.8%
H
26.0
28.6
|
L
 -4.0%
H
26.0
30.3
|
L
 29.2%
H
20.8
30.3
|
L
 199.5%
H
8.7
30.3
|
L
 299.6%
H
7.0
30.3
|
L
 189.7%
H
2.5
30.3
|
L
H
2.5
30.3
|
| Royalty Pharma PLC (Class A) |
|
20,808.3
|
48.6
|
L
 0.2%
H
48.2
49.1
|
L
 4.8%
H
46.1
49.1
|
L
 2.4%
H
44.7
49.1
|
L
 25.0%
H
38.5
49.1
|
L
 56.1%
H
29.7
49.1
|
L
 36.3%
H
24.1
49.1
|
L
 12.9%
H
24.1
49.1
|
L
H
24.1
56.5
|
| Reviva Pharma Holdings Inc |
|
9.2
|
0.7
|
L
 -11.1%
H
0.7
1.0
|
L
 -2.7%
H
0.6
1.0
|
L
 -85.3%
H
0.6
4.8
|
L
 -88.4%
H
0.6
7.8
|
L
 -93.2%
H
0.6
23.2
|
L
 -99.2%
H
0.6
185
|
L
 -99.4%
H
0.6
190
|
L
H
0.6
302
|
| Rezolute Inc |
|
298.6
|
3.1
|
L
 -0.3%
H
3.0
3.2
|
L
 4.4%
H
2.8
3.3
|
L
 -4.9%
H
2.3
3.7
|
L
 44.4%
H
1.9
4.1
|
L
 23.3%
H
1.1
11.5
|
L
 59.2%
H
0.7
11.5
|
L
 -56.5%
H
0.7
17.4
|
L
 -94.6%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.1
|
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
 6.7%
H
0.7
0.8
|
L
 -14.9%
H
0.7
1.0
|
L
 -22.3%
H
0.7
1.4
|
L
 -59.0%
H
0.7
3.3
|
L
 -99.1%
H
0.7
90.3
|
L
 -100.0%
H
0.7
11180
|
L
 -100.0%
H
0.7
16540
|
| Sunshine Biopharma Inc |
|
5.1
|
1.0
|
L
 -5.5%
H
1.0
1.1
|
L
 2.0%
H
1
1.1
|
L
 -9.6%
H
1
1.2
|
L
 -18.8%
H
1
1.4
|
L
 -33.8%
H
1
2.4
|
L
 -98.3%
H
0.1
140
|
L
 -100.0%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
52.3
|
7.4
|
L
 7.7%
H
6.8
7.8
|
L
 16.1%
H
6.2
7.8
|
L
 -14.8%
H
6.2
9.8
|
L
 -43.2%
H
6.2
14.1
|
L
 2761.5%
H
0.2
34.3
|
L
 -6.1%
H
0.2
34.3
|
L
 -24.8%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
39.8
|
0.9
|
L
H
0.9
0.9
|
L
 9.9%
H
0.8
0.9
|
L
 14.1%
H
0.7
1.0
|
L
 39.1%
H
0.6
1.0
|
L
 6.0%
H
0.6
1.3
|
L
 -74.7%
H
0.6
3.9
|
L
 -89.3%
H
0.6
10.3
|
L
 -97.9%
H
0.6
55.1
|
| Shuttle Pharma Holdings Inc |
|
4.2
|
0.8
|
L
 13.4%
H
0.7
0.8
|
L
 15.2%
H
0.5
0.8
|
L
 -18.3%
H
0.5
1.1
|
L
 -58.0%
H
0.5
4.4
|
L
 -92.2%
H
0.5
13.6
|
L
 -99.7%
H
0.5
550
|
L
H
0.5
25252
|
L
H
0.5
25252
|
| SIGA Tech Inc |
|
375.4
|
5.2
|
L
 1.4%
H
5.1
5.3
|
L
 -1.1%
H
5.1
5.5
|
L
 -17.7%
H
4.8
6.5
|
L
 -16.4%
H
4.8
7.1
|
L
 -2.8%
H
4.8
9.6
|
L
 -7.9%
H
4.2
12.8
|
L
 -20.8%
H
4.2
27.0
|
L
 1243.6%
H
0.4
27.0
|
| SILO Pharma Inc |
|
5.0
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -2.8%
H
0.3
0.4
|
L
 2.9%
H
0.2
0.4
|
L
 -67.6%
H
0.2
1.2
|
L
 -83.5%
H
0.2
4.5
|
L
 -97.7%
H
0.2
496
|
L
 -99.3%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
257.9
|
79.5
|
L
 -4.8%
H
77.5
84.6
|
L
 0.3%
H
65.1
85.3
|
L
 -10.1%
H
61.9
96
|
L
 88.5%
H
43
98.0
|
L
 16806.4%
H
0.4
98.0
|
L
 1876.6%
H
0.3
98.0
|
L
 546.0%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Soleno Therapeutics Inc |
|
2,038.6
|
39.5
|
L
 6.8%
H
36
40.1
|
L
 31.4%
H
29.8
40.1
|
L
 3.6%
H
29.4
41.1
|
L
 -16.3%
H
29.4
50.9
|
L
 -41.5%
H
29.4
90.3
|
L
 1559.2%
H
2.2
90.3
|
L
 101.0%
H
0.9
90.3
|
L
 -58.9%
H
0.9
117.8
|
| SELLAS Life Sciences Grp Inc |
|
741.7
|
4.1
|
L
 -1.9%
H
4.0
4.2
|
L
 -5.3%
H
4.0
4.4
|
L
 -25.5%
H
4.0
6.1
|
L
 -5.1%
H
3.2
6.1
|
L
 297.1%
H
1.0
6.1
|
L
 168.2%
H
0.5
6.1
|
L
 -54.7%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Soligenix Inc |
|
11.5
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -2.6%
H
1
1.3
|
L
 -19.7%
H
1
1.5
|
L
 -38.0%
H
1
6.2
|
L
 -96.0%
H
1
85.3
|
L
 -99.7%
H
1
386.4
|
L
 -99.9%
H
1
2160
|
| Sonoma Pharma Inc |
|
4.1
|
2.4
|
L
 -2.5%
H
2.1
2.4
|
L
 11.3%
H
2
2.5
|
L
 -15.4%
H
2
2.8
|
L
 -34.9%
H
2
3.9
|
L
 17.3%
H
1.8
6.9
|
L
 139.4%
H
0.1
6.9
|
L
 -73.1%
H
0.1
13.4
|
L
 -93.7%
H
0.1
74.2
|
| Synaptogenix Inc |
|
42.5
|
5.7
|
L
 -0.5%
H
5.3
6
|
L
 9.2%
H
5
6.0
|
L
 22.8%
H
3.9
7.2
|
L
 28.7%
H
3.3
7.2
|
L
 182.2%
H
1.8
12.0
|
L
 621.5%
H
0.1
12.0
|
L
 -35.2%
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc Ltd |
|
2.0
|
3.5
|
L
 -3.3%
H
3.4
3.7
|
L
 -9.5%
H
3.4
4.0
|
L
 -31.7%
H
3.4
5.9
|
L
 -71.9%
H
3.4
14.2
|
L
 -93.1%
H
3.4
94.5
|
L
 -99.8%
H
3.4
4471.7
|
L
H
3.4
41769
|
L
H
3.4
41769
|
| ARS Pharma Inc |
|
824.2
|
8.3
|
L
 2.3%
H
7.7
8.3
|
L
 2.9%
H
7.7
8.3
|
L
 -8.2%
H
7.2
9.7
|
L
 -27.8%
H
7.2
13.2
|
L
 -35.2%
H
6.7
18.9
|
L
 41.2%
H
2.6
18.9
|
L
 -81.3%
H
2.6
45.5
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
176.0
|
3.5
|
L
H
3.4
3.7
|
L
 9.7%
H
2.9
3.7
|
L
 17%
H
2.8
4.6
|
L
 72.1%
H
1.7
4.6
|
L
 35%
H
1.2
5.3
|
L
 756.1%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
2,438.9
|
23.2
|
L
 5.0%
H
21.6
23.3
|
L
 16.3%
H
19.8
23.3
|
L
 44.4%
H
15.5
23.9
|
L
 9.0%
H
15.5
24.7
|
L
 -57.3%
H
10.4
64.8
|
L
 -83.2%
H
10.4
173.3
|
L
 -69.5%
H
10.4
173.3
|
L
 16.9%
H
8
181.8
|
| Sutro Biopharma Inc |
|
394.0
|
23.8
|
L
 -4.4%
H
23.7
25.4
|
L
 -2.7%
H
23.7
26.3
|
L
 11.6%
H
19.1
26.5
|
L
 117.0%
H
10.2
26.5
|
L
 338.8%
H
5.2
26.5
|
L
 -44.8%
H
5.2
61.3
|
L
 -89.9%
H
5.2
241.7
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,906.7
|
50.5
|
L
 -1.9%
H
50.1
51.4
|
L
 1.9%
H
48.9
52.7
|
L
 -9.2%
H
46.8
56
|
L
 2.0%
H
46.8
59.7
|
L
 54.2%
H
29.2
59.7
|
L
 41.4%
H
22
59.7
|
L
 88.9%
H
22
59.7
|
L
 211.2%
H
13.1
61.3
|
| Savara Inc |
|
1,137.9
|
5.6
|
L
 -0.4%
H
5.5
5.7
|
L
 8.2%
H
4.9
5.7
|
L
 -1.1%
H
4.8
5.8
|
L
 -1.4%
H
4.8
6.5
|
L
 95.1%
H
1.9
7
|
L
 225.1%
H
1.6
7
|
L
 147.1%
H
1.0
7
|
L
 -71.6%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
1.6
|
1.9
|
L
 5%
H
1.8
1.9
|
L
 45.4%
H
1.3
2.0
|
L
 -5.5%
H
1.3
2.2
|
L
 8.6%
H
0.0
7.0
|
L
 -22.9%
H
0.0
7.0
|
L
 -72%
H
0.0
9.4
|
L
 -96.0%
H
0.0
57
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
115,230.0
|
47.9
|
L
 0.3%
H
47.3
48.0
|
L
 2.4%
H
46.5
48.4
|
L
 3.6%
H
43.3
48.4
|
L
 -0.7%
H
43.3
49.4
|
L
 -7.9%
H
43.3
55.7
|
L
 -11.7%
H
42.6
60.1
|
L
 -3.0%
H
36.9
60.1
|
L
 14.5%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
276.4
|
5.1
|
L
 1.4%
H
4.9
5.1
|
L
 3.4%
H
4.8
5.4
|
L
 -17.6%
H
4.8
6.2
|
L
 -5.0%
H
4.7
7.5
|
L
 31.0%
H
2.8
7.8
|
L
 69.8%
H
1.0
10.5
|
L
 -67.2%
H
1.0
17.7
|
L
 -98.5%
H
1.0
465.2
|
| Tarsus Pharma Inc |
|
2,984.1
|
70.1
|
L
 -0.1%
H
69.0
71.4
|
L
 5.8%
H
64.6
72.1
|
L
 -8.0%
H
61.5
76.5
|
L
 -13.2%
H
60.5
82.3
|
L
 49.1%
H
38.5
85.3
|
L
 461.9%
H
11.3
85.3
|
L
 112.9%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
824.9
|
16.0
|
L
 1.1%
H
15.7
16.2
|
L
 6.2%
H
14.7
16.5
|
L
 17.3%
H
13.3
16.5
|
L
 -11.7%
H
13.1
21.0
|
L
 89.8%
H
7.9
21.0
|
L
 45.8%
H
7.4
21.0
|
L
 -20.4%
H
6.1
22.7
|
L
 -21.6%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
258.3
|
15.0
|
L
 -6.1%
H
14.8
16.0
|
L
 0.8%
H
13.6
17.0
|
L
 25.7%
H
10.4
17.0
|
L
 35.9%
H
10.4
18.4
|
L
 159.0%
H
4.6
18.4
|
L
 -50.6%
H
2.8
61.2
|
L
 -99.5%
H
2.8
3952
|
L
 -100.0%
H
2.8
94080
|
| TG Therapeutics Inc |
|
5,354.3
|
33.5
|
L
 -0.2%
H
33.1
34.1
|
L
 5.6%
H
31.3
34.3
|
L
 14.9%
H
26.8
34.3
|
L
 14.5%
H
26.8
34.3
|
L
 -10.2%
H
25.3
46.5
|
L
 104.1%
H
6.5
46.5
|
L
 -31.5%
H
3.5
49.9
|
L
 267.3%
H
3.3
56.7
|
| Alpha Teknova Inc |
|
169.3
|
3.2
|
L
 7.9%
H
2.9
3.2
|
L
 16.6%
H
2.6
3.2
|
L
 35.0%
H
2.0
3.2
|
L
 -19.0%
H
1.9
4.3
|
L
 -32.5%
H
1.9
7.5
|
L
 14.1%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
159.1
|
1.3
|
L
H
1.2
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 -12.6%
H
1.2
1.5
|
L
 -21.9%
H
1.2
1.8
|
L
 33.0%
H
0.7
2.6
|
L
 56.3%
H
0.4
2.6
|
L
 -54.5%
H
0.4
3.3
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
197.5
|
13.9
|
L
 1.6%
H
13.1
14.0
|
L
 7.9%
H
11.6
14.9
|
L
 -0.6%
H
11.6
17
|
L
 -16.0%
H
11.6
20.0
|
L
 -11.1%
H
11.6
70.0
|
L
 -99.9%
H
0.2
12000
|
L
 -100.0%
H
0.2
908800
|
L
 -100.0%
H
0.2
2412800000
|
| Tenaya Therapeutics Inc |
|
151.9
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 6.1%
H
0.6
0.7
|
L
 20.7%
H
0.6
1.0
|
L
 -5.4%
H
0.5
1.0
|
L
 40%
H
0.4
2.4
|
L
 -74.1%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
22.8
|
1.6
|
L
 -1.9%
H
1.6
1.6
|
L
 -8.1%
H
1.5
1.7
|
L
 -32.1%
H
1.5
2.5
|
L
 -46.1%
H
1.5
3.2
|
L
 160.7%
H
0.4
12.2
|
L
 -30.9%
H
0.2
12.2
|
L
 -91.7%
H
0.2
41
|
L
 -99.9%
H
0.2
2623.5
|
| Travere Therapeutics Inc |
|
2,807.8
|
30.4
|
L
 -3.1%
H
30.2
31.4
|
L
 11.7%
H
27.1
31.8
|
L
 8.0%
H
26.2
31.8
|
L
 -23.0%
H
22.6
40.8
|
L
 103.1%
H
12.9
42.1
|
L
 39.4%
H
5.1
42.1
|
L
 18.3%
H
5.1
42.1
|
L
 110.8%
H
5.1
42.1
|
| TherapeuticsMD Inc |
|
23.1
|
2
|
L
H
1.9
2.1
|
L
 -4.8%
H
1.9
2.2
|
L
 -7.4%
H
1.9
2.4
|
L
 21.2%
H
1.6
3.0
|
L
 127.3%
H
0.8
3.0
|
L
 -45.5%
H
0.7
4.7
|
L
 -97.1%
H
0.7
73.5
|
L
 -99.4%
H
0.7
464.5
|
| Universe Pharma INC |
|
1.8
|
3.2
|
L
 15.8%
H
2.8
3.2
|
L
 16.2%
H
2.6
3.2
|
L
 19.7%
H
2
3.3
|
L
 -24.0%
H
2
5.0
|
L
 -8.4%
H
2
11
|
L
 -63.8%
H
0.1
64.8
|
L
 -96.0%
H
0.1
84.8
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
24,754.3
|
564.8
|
L
 -1.0%
H
551.3
577.9
|
L
 8.0%
H
551.3
607.9
|
L
 15.2%
H
471.3
607.9
|
L
 13.7%
H
455.6
607.9
|
L
 93.1%
H
267.0
607.9
|
L
 148.6%
H
204.4
607.9
|
L
 193.7%
H
158.4
607.9
|
L
 397.5%
H
74.3
607.9
|
| Vericel Corp |
|
1,738.8
|
34.1
|
L
 4.9%
H
31.3
35.2
|
L
 16.4%
H
29.2
35.2
|
L
 -2.4%
H
29.0
35.2
|
L
 -4.1%
H
29.0
41.7
|
L
 -18.6%
H
29.0
46.0
|
L
 17.7%
H
28.4
63
|
L
 -35.8%
H
17.3
68.9
|
L
 817.7%
H
2.0
68.9
|
| Veru Inc |
|
36.8
|
2.3
|
L
 0.9%
H
2.2
2.3
|
L
 9.6%
H
2.1
2.3
|
L
 -8.8%
H
2.1
2.6
|
L
 0.9%
H
2.1
2.8
|
L
 -59.8%
H
2.1
7.4
|
L
 -79.4%
H
2.1
19.2
|
L
 -98.0%
H
2.1
245.5
|
L
 -87.4%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
70.5
|
2.1
|
L
 -0.9%
H
2.1
2.2
|
L
 6.6%
H
1.8
2.4
|
L
 -31.7%
H
1.8
3.5
|
L
 -50.2%
H
1.8
4.3
|
L
 -50.4%
H
1.8
9.5
|
L
 502.9%
H
0.1
29.3
|
L
 -63.2%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
4,021.3
|
34.8
|
L
 5.6%
H
32
35.2
|
L
 7.0%
H
29.9
35.2
|
L
 8.3%
H
29.9
37.5
|
L
 -1.8%
H
25.8
37.5
|
L
 53.9%
H
18.9
43.2
|
L
 104.1%
H
8.3
99.4
|
L
 454.1%
H
2.0
99.4
|
L
 2235.6%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
413.8
|
7
|
L
 -1.0%
H
6.8
7
|
L
 1.3%
H
6.6
7.2
|
L
 -14.6%
H
6.6
9.9
|
L
 -15.2%
H
5.7
9.9
|
L
 69.1%
H
3.8
9.9
|
L
 4.5%
H
3.3
9.9
|
L
 -55.4%
H
3.3
21.9
|
L
 -16.6%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
94.0
|
5.5
|
L
 -0.4%
H
5.2
5.5
|
L
 24.9%
H
4.4
5.6
|
L
 2.6%
H
4.2
6.6
|
L
 -34.1%
H
4.2
9.0
|
L
 932.1%
H
0.4
9.8
|
L
 -13.2%
H
0.4
11.4
|
L
 -64.3%
H
0.4
17
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
1,925.6
|
18.8
|
L
 -1.6%
H
18.4
19.2
|
L
 -31.2%
H
17.0
19.8
|
L
 -38.0%
H
17.0
30.8
|
L
 -38.6%
H
17.0
34.3
|
L
 57.1%
H
9.9
34.3
|
L
 -25.4%
H
9.9
34.3
|
L
 19.5%
H
9.5
39
|
L
 -82.9%
H
4.7
270
|
| Vertex Pharma |
|
111,447.3
|
438.7
|
L
 -1.9%
H
436.6
449.6
|
L
 1.3%
H
432.1
454.0
|
L
 -8.2%
H
431.0
507.9
|
L
 -3.0%
H
429
507.9
|
L
 -7.6%
H
362.5
510.8
|
L
 39.5%
H
314.3
519.9
|
L
 105.9%
H
176.4
519.9
|
L
 429.4%
H
71.5
519.9
|
| Viatris |
|
15,474.7
|
13.4
|
L
 -1.4%
H
13.3
13.7
|
L
 3.0%
H
12.9
13.8
|
L
 -8.6%
H
12.9
14.7
|
L
 7.9%
H
12.2
16.5
|
L
 76.4%
H
6.9
16.5
|
L
 41.0%
H
6.9
16.5
|
L
 -3.3%
H
6.9
16.5
|
L
 -71.5%
H
6.9
50.4
|
| vTv Therapeutics Inc (Class A) |
|
162.2
|
41.2
|
L
 1.6%
H
40.2
43.1
|
L
 6.9%
H
36.7
43.1
|
L
 14.4%
H
31.2
43.1
|
L
 4.0%
H
28.8
44
|
L
 153.2%
H
14
44
|
L
 5178.2%
H
0.4
44
|
L
 1324.6%
H
0.4
44
|
L
 712.0%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
20.0
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 1.7%
H
0.6
0.6
|
L
 1.7%
H
0.6
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 -61.5%
H
0.3
2.0
|
L
 -79.0%
H
0.3
8.7
|
L
 -99.5%
H
0.3
126.7
|
L
H
0.3
2869.9
|
| Vaccitech PLC (ADR) |
|
23.1
|
0.6
|
L
 11.1%
H
0.5
0.6
|
L
 9.1%
H
0.5
0.6
|
L
H
0.5
0.7
|
L
 -18.9%
H
0.5
0.8
|
L
 -36.2%
H
0.5
2.9
|
L
 -73.2%
H
0.5
5.1
|
L
H
0.5
18.0
|
L
H
0.5
18.0
|
| Xenetic Biosciences Inc |
|
6.9
|
3.0
|
L
 6.7%
H
2.7
3.1
|
L
 10.7%
H
2.7
3.1
|
L
 24.4%
H
2.2
3.5
|
L
 40%
H
2.1
3.5
|
L
 22.4%
H
1.9
13.9
|
L
 -31.7%
H
1.9
13.9
|
L
 -85.7%
H
1.9
56.8
|
L
 -99.8%
H
1.9
1207.8
|
| Xenon Pharma Inc |
|
5,425.0
|
56.9
|
L
 0.3%
H
55.9
57.4
|
L
 4.4%
H
53.6
59.4
|
L
 32.1%
H
41.1
64.0
|
L
 27.8%
H
39.3
64.0
|
L
 93.4%
H
26.7
64.0
|
L
 57.6%
H
26.7
64.0
|
L
 201.0%
H
14.7
64.0
|
L
 700.7%
H
2.1
64.0
|
| Xilio Therapeutics Inc |
|
49.2
|
8.5
|
L
 0.4%
H
8.2
8.6
|
L
 2.3%
H
8.0
8.9
|
L
 11.5%
H
6.5
9.3
|
L
 -9.6%
H
6.5
10.4
|
L
 -10.6%
H
6.5
16.5
|
L
 -81.0%
H
6.5
51.4
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XOMA Corp |
|
393.0
|
33.0
|
L
 -0.3%
H
32.1
33.4
|
L
 9.3%
H
28.6
34
|
L
 24.7%
H
25.4
34
|
L
 17.8%
H
22.3
34
|
L
 69.7%
H
18.4
39.9
|
L
 66.7%
H
13.5
39.9
|
L
 -18.8%
H
13.5
41.2
|
L
 99.5%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
3.0
|
0.4
|
L
 2.4%
H
0.4
0.5
|
L
 13.2%
H
0.4
0.5
|
L
 7.5%
H
0.3
0.5
|
L
 -24.6%
H
0.3
0.6
|
L
 -52.2%
H
0.3
1.4
|
L
 -18.9%
H
0.3
7
|
L
 -75.7%
H
0.3
8.2
|
L
H
0.3
8.2
|
| Zevra Therapeutics Inc |
|
551.9
|
9.4
|
L
 -0.1%
H
9.2
9.4
|
L
 2.6%
H
8.7
9.6
|
L
 5.3%
H
8.4
11.4
|
L
 12.7%
H
8.1
11.4
|
L
 34.1%
H
6.2
13.2
|
L
 72.5%
H
3.9
13.2
|
L
 -1.1%
H
3.9
15.7
|
L
 -96.3%
H
1.9
316
|
| Zymeworks BC Inc |
|
1,917.0
|
25.8
|
L
 -0.5%
H
25.5
26.7
|
L
 6.7%
H
23.6
26.7
|
L
 2.3%
H
22.4
28
|
L
 -3.1%
H
21.9
28
|
L
 135.6%
H
9.0
28.5
|
L
 174.5%
H
6.0
28.5
|
L
 -18.0%
H
4.1
39.4
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
173.4
|
5.3
|
L
 1.5%
H
5.1
5.3
|
L
 8.8%
H
4.5
5.4
|
L
 -7.6%
H
4.5
6
|
L
 -11.2%
H
4.5
7.2
|
L
 155.8%
H
1.7
11.4
|
L
 -30.2%
H
1.7
20.7
|
L
 -30.2%
H
1.7
20.7
|
L
 -30.2%
H
1.7
20.7
|
| CervoMed Inc |
|
38.3
|
4.1
|
L
 3.5%
H
3.9
4.4
|
L
 11.3%
H
3.5
4.4
|
L
 3.0%
H
3.5
5.1
|
L
 -46.9%
H
3.5
8.2
|
L
 -62.6%
H
3.5
13.1
|
L
 -28.4%
H
1.8
26.4
|
L
 -94.0%
H
1.8
69
|
L
 -100.0%
H
1.8
17437.5
|
| Dianthus Therapeutics Inc |
|
4,553.0
|
86
|
L
 1.7%
H
81.8
87.5
|
L
 6%
H
77.6
88.5
|
L
 38.6%
H
59.4
88.5
|
L
 116.7%
H
35.8
88.5
|
L
 433.5%
H
13.4
88.5
|
L
 11215.8%
H
6.6
88.5
|
L
 11215.8%
H
6.6
88.5
|
L
 11215.8%
H
6.6
88.5
|
| Neumora Therapeutics Inc |
|
364.1
|
2
|
L
 -4.3%
H
2.0
2.1
|
L
 -14.2%
H
1.8
2.2
|
L
 -34.4%
H
1.8
3.5
|
L
 20.5%
H
1.5
3.7
|
L
 170.3%
H
0.6
3.7
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
3.2
|
3.2
|
L
 25.8%
H
2.5
3.5
|
L
 -0.9%
H
2.5
3.6
|
L
 58.5%
H
1.8
6.3
|
L
 -39.6%
H
1.7
7.3
|
L
 -94.7%
H
1.7
128.3
|
L
 -99.8%
H
1.7
1590
|
L
 -99.8%
H
1.7
1590
|
L
 -99.8%
H
1.7
1590
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
24.5
|
0.6
|
L
 11.1%
H
0.5
0.6
|
L
 9.1%
H
0.5
0.6
|
L
H
0.5
0.7
|
L
 -18.9%
H
0.5
0.8
|
L
 -11.8%
H
0.5
2.9
|
L
 -83.5%
H
0.5
5.1
|
L
 -83.5%
H
0.5
5.1
|
L
 -83.5%
H
0.5
5.1
|
| Viamet Pharma Corp |
|
1,050.1
|
9.9
|
L
 5.2%
H
9.1
10
|
L
 4.6%
H
9.1
10
|
L
 -5.2%
H
9.1
12.1
|
L
 -5.2%
H
9.1
12.1
|
L
 -5.2%
H
9.1
12.1
|
L
 -5.2%
H
9.1
12.1
|
L
 -5.2%
H
9.1
12.1
|
L
 -5.2%
H
9.1
12.1
|
| Onconetix Inc |
|
1.1
|
1.5
|
L
 -19.2%
H
1.3
1.7
|
L
 -21.7%
H
1.2
1.9
|
L
 -55.0%
H
1.2
6.7
|
L
 -81.1%
H
1.2
11.5
|
L
 -95.0%
H
1.2
74.4
|
L
 -100.0%
H
1.2
26860
|
L
 -99.8%
H
1.2
1545300
|
L
 -99.8%
H
1.2
1545300
|
| Talphera Inc |
|
36.0
|
0.7
|
L
 -7.7%
H
0.7
0.8
|
L
 -2.7%
H
0.7
0.8
|
L
 -20.9%
H
0.7
0.9
|
L
 -37.9%
H
0.7
1.3
|
L
 41.2%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| ArriVent BioPharma Inc |
|
1,100.2
|
24.9
|
L
 2.8%
H
23.5
25.3
|
L
 16.2%
H
20.7
25.3
|
L
 -6.3%
H
20.7
26.9
|
L
 19.7%
H
18.2
27.2
|
L
 51.6%
H
15.5
27.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
23.4
|
0.7
|
L
 6.1%
H
0.6
0.7
|
L
 20.7%
H
0.6
0.7
|
L
 -5.4%
H
0.6
0.8
|
L
 -20.5%
H
0.6
1.2
|
L
 -46.2%
H
0.6
5.8
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
| Actuate Therapeutics Inc |
|
58.8
|
2.5
|
L
 -0.4%
H
2.3
2.6
|
L
 15.4%
H
2.1
2.9
|
L
 -18.7%
H
2.1
3.2
|
L
 -58.9%
H
2.1
7.1
|
L
 -64.0%
H
2.1
12.0
|
L
H
2.1
12.0
|
L
H
2.1
12.0
|
L
H
2.1
12.0
|
| Bicara Therapeutics Inc |
|
1,405.6
|
21.5
|
L
 4.7%
H
19.9
21.5
|
L
 16.9%
H
17.6
21.5
|
L
 15.8%
H
17.6
21.5
|
L
 31.1%
H
13.8
21.5
|
L
 103.1%
H
7.8
21.5
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq Ltd |
|
7.3
|
0.7
|
L
 -8.1%
H
0.7
0.7
|
L
 -6.9%
H
0.7
0.8
|
L
 -13.9%
H
0.6
0.8
|
L
 -19.1%
H
0.6
1.4
|
L
 -24.4%
H
0.6
4.1
|
L
H
0.6
5.5
|
L
H
0.6
5.5
|
L
H
0.6
5.5
|
| Septerna Inc |
|
1,130.7
|
25.2
|
L
 3.3%
H
23.9
25.3
|
L
 5.5%
H
22.9
25.3
|
L
 -12.6%
H
22.9
30
|
L
 -10.0%
H
22.9
32.6
|
L
 359.5%
H
4.7
32.6
|
L
H
4.2
32.6
|
L
H
4.2
32.6
|
L
H
4.2
32.6
|
| Alpha Cognition Inc |
|
130.0
|
6.0
|
L
 0.3%
H
5.9
6.4
|
L
 17.7%
H
4.9
6.4
|
L
 2.1%
H
4.9
6.4
|
L
 -8%
H
4.5
6.8
|
L
 23.8%
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic Intl Corp |
|
278.3
|
3.5
|
L
H
3.4
3.7
|
L
 9.7%
H
2.9
3.7
|
L
 17%
H
2.8
4.6
|
L
 72.1%
H
1.7
4.6
|
L
 35%
H
1.2
5.3
|
L
 35%
H
1.2
5.3
|
L
 35%
H
1.2
5.3
|
L
 35%
H
1.2
5.3
|
| BeiGene Ltd (ADR) |
|
34,497.7
|
310.8
|
L
 0.8%
H
306.3
316.0
|
L
 9.8%
H
281.1
316.0
|
L
 3.9%
H
271.5
316.0
|
L
 -0.1%
H
271.5
372.7
|
L
 30.3%
H
196.5
385.2
|
L
 68.3%
H
172.7
385.2
|
L
 68.3%
H
172.7
385.2
|
L
 68.3%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
12.7
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 5.7%
H
0.3
0.4
|
L
 -17.8%
H
0.3
0.5
|
L
 -63.4%
H
0.3
1.1
|
L
 -36.2%
H
0.3
3.3
|
L
 -36.2%
H
0.3
3.3
|
L
 -36.2%
H
0.3
3.3
|
L
 -36.2%
H
0.3
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
2,549.8
|
27.3
|
L
 4.0%
H
26.5
27.3
|
L
 18.6%
H
23.2
27.3
|
L
 22.8%
H
19.1
27.3
|
L
 3.6%
H
19.1
28.8
|
L
 30.4%
H
17.6
48.5
|
L
 57.2%
H
17
48.5
|
L
 57.2%
H
17
48.5
|
L
 57.2%
H
17
48.5
|
| Maze Therapeutics Inc |
|
1,427.1
|
28.7
|
L
 -1.2%
H
28
29.8
|
L
 -5.5%
H
28
31.2
|
L
 -38.2%
H
28
53.7
|
L
 -27.8%
H
28
53.7
|
L
 216.5%
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
93.8
|
4.3
|
L
 5.1%
H
3.9
4.3
|
L
 21.1%
H
3.5
4.3
|
L
 -23.8%
H
3.4
6.5
|
L
 -67.4%
H
3.4
16.6
|
L
 -47.3%
H
3.4
17.9
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
7.3
|
0.3
|
L
 3.0%
H
0.3
0.3
|
L
 -15%
H
0.3
0.3
|
L
 -15%
H
0.3
0.4
|
L
 -15%
H
0.3
0.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
| Jyong Biotech Ltd |
|
181.9
|
2.5
|
L
 7.5%
H
2.1
2.5
|
L
 26.3%
H
1.9
2.5
|
L
 7.5%
H
1.7
2.6
|
L
 -28.2%
H
1.4
4.3
|
L
 -75.8%
H
1.4
67
|
L
 -75.8%
H
1.4
67
|
L
 -75.8%
H
1.4
67
|
L
 -75.8%
H
1.4
67
|
| Black Titan Corp |
|
13.3
|
1.3
|
L
 -6.3%
H
1.3
1.4
|
L
 5.6%
H
1.3
1.8
|
L
 -10.1%
H
1.2
1.8
|
L
 -27.3%
H
1.2
3.3
|
L
 -94.5%
H
1.2
23.5
|
L
 -94.5%
H
1.2
23.5
|
L
 -94.5%
H
1.2
23.5
|
L
 -94.5%
H
1.2
23.5
|
| MapLight Therapeutics Inc |
|
898.4
|
21.2
|
L
 1.6%
H
20.3
21.8
|
L
 14.1%
H
18.0
21.8
|
L
 17.5%
H
16.3
21.8
|
L
 26.2%
H
15.5
21.8
|
L
 15.4%
H
12.2
21.8
|
L
 15.4%
H
12.2
21.8
|
L
 15.4%
H
12.2
21.8
|
L
 15.4%
H
12.2
21.8
|
| NovaBridge Biosciences ADR |
|
280.2
|
2.4
|
L
 -1.2%
H
2.4
2.6
|
L
 -4.3%
H
2.1
2.7
|
L
 -21.9%
H
2.1
3.9
|
L
 -43.1%
H
2.1
5.2
|
L
 -46.6%
H
2.1
5.2
|
L
 -46.6%
H
2.1
5.2
|
L
 -46.6%
H
2.1
5.2
|
L
 -46.6%
H
2.1
5.2
|
| Evommune Inc |
|
854.4
|
23.7
|
L
 5.8%
H
22.1
23.9
|
L
 6.9%
H
21.5
25
|
L
 0.6%
H
20.6
27.6
|
L
 37.0%
H
14.8
33.2
|
L
 17.3%
H
13.9
33.2
|
L
 17.3%
H
13.9
33.2
|
L
 17.3%
H
13.9
33.2
|
L
 17.3%
H
13.9
33.2
|
| Aktis Oncology Inc |
|
-
|
17.4
|
L
 1.8%
H
16.3
17.5
|
L
 14.4%
H
14.7
19.4
|
L
 -16.7%
H
14.7
21.6
|
L
 -22.5%
H
14.7
24.5
|
L
 -22.5%
H
14.7
24.5
|
L
 -22.5%
H
14.7
24.5
|
L
 -22.5%
H
14.7
24.5
|
L
 -22.5%
H
14.7
24.5
|
| Helus Pharma Inc |
|
255.5
|
5.1
|
L
 2.6%
H
4.8
5.3
|
L
 13.3%
H
4.3
5.3
|
L
 -40.0%
H
4.3
6.8
|
L
 -32.0%
H
4.3
8.6
|
L
 -32.0%
H
4.3
8.6
|
L
 -32.0%
H
4.3
8.6
|
L
 -32.0%
H
4.3
8.6
|
L
 -32.0%
H
4.3
8.6
|
| NervGen Pharma Corp |
|
337.4
|
4.3
|
L
 -2.3%
H
4.1
4.3
|
L
 16.4%
H
3.6
4.4
|
L
 -0.2%
H
3.5
4.4
|
L
 -25.9%
H
3.5
5.9
|
L
 -25.9%
H
3.5
5.9
|
L
 -25.9%
H
3.5
5.9
|
L
 -25.9%
H
3.5
5.9
|
L
 -25.9%
H
3.5
5.9
|
| Veradermics Inc |
|
2,251.6
|
64.2
|
L
 9.2%
H
57.5
64.2
|
L
 -2.0%
H
54.8
66.6
|
L
 35.6%
H
47.1
69.4
|
L
 70.0%
H
35.1
69.4
|
L
 70.0%
H
35.1
69.4
|
L
 70.0%
H
35.1
69.4
|
L
 70.0%
H
35.1
69.4
|
L
 70.0%
H
35.1
69.4
|
| Eikon Therapeutics Inc |
|
536.0
|
9.9
|
L
 -1.8%
H
9.6
10.5
|
L
 0.9%
H
9.5
11.1
|
L
 -34.7%
H
9.5
16.2
|
L
 -34%
H
9.5
16.5
|
L
 -34%
H
9.5
16.5
|
L
 -34%
H
9.5
16.5
|
L
 -34%
H
9.5
16.5
|
L
 -34%
H
9.5
16.5
|
| Satellos Bioscience Inc |
|
121.1
|
5.9
|
L
 -2.8%
H
5.8
6
|
L
 -5.2%
H
5.6
6.8
|
L
 -52.2%
H
5.6
13.0
|
L
 -47.8%
H
5.6
13.4
|
L
 -47.8%
H
5.6
13.4
|
L
 -47.8%
H
5.6
13.4
|
L
 -47.8%
H
5.6
13.4
|
L
 -47.8%
H
5.6
13.4
|